Document:

<PAGE>

                                                                 EXHIBIT 10.83

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

                                  ------------

                               CORIXA CORPORATION

                                       AND

                               JAPAN TOBACCO INC.

                                  ------------

                              AMENDED AND RESTATED

                                     LICENSE

                                       AND

                             COLLABORATIVE RESEARCH

                                    AGREEMENT

                                  ------------

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                    PAGE
<S>                                                                 <C>
 1. DEFINITIONS...................................................     1

 2. LICENSE GRANTS.................................................    6

 3. UPFRONT, MILESTONE AND NET PROCEEDS PAYMENTS..................    10

 4. ROYALTY PAYMENTS..............................................    12

 5. REPORTS, PAYMENTS, ACCOUNTING AND DILIGENCE...................    15

 6. MANUFACTURING; SUPPLY.........................................    17

 7. PATENTS; PROSECUTION AND LITIGATION...........................    17

 8. DISCLOSURE; CONFIDENTIALITY; PUBLICITY; PUBLICATIONS..........    19

 9. GOVERNING LAW; ARBITRATION....................................    21

10. MISCELLANEOUS.................................................    21

11. NOTICES.......................................................    23

12. ASSIGNMENT....................................................    24

13. WARRANTIES, REPRESENTATIONS AND COVENANTS.....................    24

14. TERM AND TERMINATION..........................................    25

15. RIGHTS AND DUTIES UPON TERMINATION............................    27

16. INDEMNIFICATION...............................................    27
</TABLE>

                                      -i-

<PAGE>

                                    EXHIBITS

         Exhibit A                  Antigens

         Exhibit B-1                Corixa Patents

         Exhibit B-2                Licensed Patents

         Exhibit C                  JT Patents

         Exhibit D                  [*] Antigen

         Exhibit E                  Non-exclusive Third Party License Agreements

-----------------------------------
* Confidential treatment requested.

                                      -ii-

<PAGE>

                              AMENDED AND RESTATED
                  LICENSE AND COLLABORATIVE RESEARCH AGREEMENT

         This AMENDED AND RESTATED LICENSE AND COLLABORATIVE RESEARCH AGREEMENT
(together with the attachments and exhibits hereto, the "Agreement") made and
entered into as of December 19, 2002 (the "Effective Date") by and between
Corixa Corporation, a corporation organized and existing under the laws of the
State of Delaware and having its principal office at 1124 Columbia Street, Suite
200, Seattle, Washington, and Japan Tobacco Inc., a corporation organized and
existing under the laws of Japan and having its principal office at 2-2-1
Toranomon, Minato-ku, Tokyo 105-8422, Japan, amends and restates that certain
License and Collaborative Research Agreement entered into as of June 15, 1999 by
and between Corixa and JT (the "Initial Agreement").

                                    RECITALS

         WHEREAS, the parties desire that all right, title and interest to the
Corixa Products, Corixa Patents, Corixa Know-How, and all other research results
and materials related to the Initial Agreement shall revert or be transferred to
and owned solely by Corixa;

         WHEREAS, the parties desire that JT retain an exclusive license to the
[*] Vaccine in Japan; and

         WHEREAS, the parties desire to amend and restate the Initial Agreement
on the terms set forth below;

         NOW, THEREFORE, for and in consideration of the mutual observance of
the covenants hereinafter set forth and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

1.       DEFINITIONS.

         All references to particular Exhibits, Articles and Sections shall mean
the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise
specified. References to this "Agreement" include the Exhibits. For the purposes
of this Agreement, the following words and phrases shall have the following
meanings:

         1.1      "Affiliate" of an entity shall mean, for so long as one of the
following relationships is maintained, any corporation or other business entity
owned by, owning, or under common ownership with a party to this Agreement to
the extent of at least fifty percent (50%) of the equity (or such lesser
percentage that is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) having the power to vote on or direct the affairs of
the entity and any person, firm, partnership, corporation, or other entity
actually controlled by, controlling or under common control with a party to this
Agreement. Notwithstanding the

-----------------------------------
* Confidential treatment requested.

<PAGE>

foregoing, the government of Japan shall not be considered an Affiliate of JT
for purposes of this Agreement.

         1.2      "Antibody" shall mean an immunoglobulin or fragment or
derivative thereof capable of binding to a specific Antigen.

         1.3      "Antigen(s)" shall mean the antigens listed on Exhibit A
hereto and/or protein and/or other physical form based on such antigens, such as
peptides and/or nucleic acids(s) (DNA, RNA) delivered in any form (including
recombinant vectors) to the extent such antigens are covered by one (1) or more
Valid Claim(s) of any of the Corixa Patents.

         1.4      "BLA" shall mean a Biological License Application as defined
in the FD&C Act and the regulations promulgated thereunder.

         1.5      "Corixa" shall mean Corixa Corporation and each of its
Affiliates.

         1.6      "Corixa Antibody Product" shall mean any product incorporating
an Antibody.

         1.7      "Corixa Intellectual Property" shall mean the Corixa Know-How
and the Corixa Patents.

         1.8      "Corixa Know-How" shall mean all technical information,
materials and know-how owned and/or controlled by Corixa that is necessary or
useful in connection with the [*] Vaccine, and shall include, without limitation
all clinical data packages provided by Corixa to JT hereunder, all chemical,
pharmacological, toxicological, clinical, assay, control and manufacturing data
and any other information, biological materials or manufacturing or related
technology relating to any Licensed Product and that can reasonably be deemed to
be useful for the development and commercialization of any Licensed Product and
strains, samples, analytical tools, libraries, clones, etc. Notwithstanding
anything to the contrary, Corixa Know-How shall not include any Corixa Adjuvant
Know-How or Corixa Microsphere Know-How. As used herein, "Corixa Adjuvant
Know-How" shall mean any technical information, materials or know-how
exclusively related to any adjuvant owned or controlled by Corixa, including
without limitation the protein Leishmania Elongation Initiation Factor, known as
LeIF, MPL, or any synthetic adjuvant. As used herein, "Corixa Microsphere
Know-How" shall mean any technical information, materials or know-how
exclusively related to any encapsulated antigen delivery system owned, developed
or licensed by Corixa.

         1.9      "Corixa Licensed Field" shall mean solid tumors in humans.

         1.10     "Corixa Patents" shall mean all patents and patent
applications that are identified on Exhibit B-1 and/or Exhibit B-2.

         1.11     "Corixa Products" shall mean all Corixa Antibody Products and
Corixa Vaccine Products.

-----------------------------------
* Confidential treatment requested.

                                       2

<PAGE>

         1.12     "Corixa Vaccine Product" shall mean any in vivo administered
prophylactic and/or therapeutic cancer Vaccine that includes at least one (1)
Antigen.

         1.13     "Damages" shall have the meaning given to it in Section 16.1.

         1.14     "Dispute" shall have the meaning given to it in Section 9.

         1.15     "Effective Date" shall mean that date first set forth in this
Agreement.

         1.16     "Europe" shall mean the countries of Austria, Belgium,
Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary,
Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal,
Romania, Spain, Sweden, Switzerland, the United Kingdom, all countries,
territories and republics of the former Yugoslavia, and any and all former
republics of the Soviet Union.

         1.17     "FDA" shall mean the United States Food and Drug
Administration.

         1.18     "FD&C Act" shall mean the United States Food, Drug and
Cosmetic Act.

         1.19     "GAAP" shall mean the conventions, rules and procedures
governing accounting practices as established, and revised or amended, by the
U.S. Financial Accounting Standards Board or the U.S. Securities and Exchange
Commission.

         1.20     "Health Ministry" shall have the meaning given to it in
Section 5.3

         1.21     "Indemnified Party" shall have the meaning given to it in
Section 16.1.

         1.22     "Indemnifying Party" shall have the meaning given to it in
Section 16.2.

         1.23     "Initial Agreement" shall have the meaning set forth in the
preamble to this Agreement.

         1.24     "Initial Agreement Activities" shall mean activities,
including any research, conducted under or in connection with, the Initial
Agreement by Corixa or JT, solely, jointly or with a Third Party.

         1.25     "Initial Agreement Effective Date" shall mean July 15, 1999.

         1.26     "Insured Party" shall have the meaning given to it in Section
13.6.

         1.27     "Joint Inventions" shall mean patentable inventions,
discoveries or technology(ies) that arose from the performance of the activities
conducted by Corixa under the Initial Agreement and which were made jointly by
employees or agents of Corixa and JT during its term.

         1.28     "Joint Research Program Patents" shall mean all patents and
patent applications which cover Joint Inventions and which generically or
specifically claim all or any part of any Licensed Product, a process for
manufacturing any Licensed Product, and intermediates used in such process or a
use of any Licensed Product. Included with the definition of Joint Research

                                       3

<PAGE>

Program Patents are any continuations, continuations-in-part (solely to the
extent such continuation(s)-in-part contains subject matter on which claims
issuing obtain the benefit of a priority date of any other patent application
included herein), divisions, patents of addition, reissues, renewals or
extensions and/or foreign counterparts thereof. Also included within the
definition of Joint Research Program Patents are all patents and patent
applications which cover Joint Inventions and which generically or specifically
claim any inventions, including improvements on any Licensed Product or uses of
any Licensed Product or intermediates or manufacturing processes required or
useful for production of any Licensed Product. In no event shall Joint Research
Program Patents be deemed to include Corixa Patents or JT Patents.

         1.29     "JT" shall mean Japan Tobacco Inc. and each of its Affiliates.

         1.30     "JT Licensed Field" shall mean solid tumors in humans;
provided, however, that the JT Licensed Field shall specifically exclude the use
of (a) any [*] Vaccine as an ex vivo adoptive immunotherapeutic and prophylactic
for any and all cancers, including the use of dendritic cells as vaccines, (b)
any [*] Vaccine as a diagnostic and (c) Antigens as targets for small molecules,
therapeutics and/or prophylactics.

         1.31     "JT Patents" shall mean all patents and patent applications
(a) (x) that cover patentable inventions or discoveries made by JT solely or
together with a Third Party in the course of the Initial Agreement Activities or
(y) that cover patentable inventions or discoveries that generically or
specifically claim all or any part of any [*] Vaccine, a process for
manufacturing any [*] Vaccine, intermediates used in such process or a use of
any [*] Vaccine, and (b) which are now or become owned and/or controlled by JT
and/or under which JT otherwise has, now or in the future, the right to grant
licenses. Included within the definition of JT Patents are any continuations,
continuations-in-part, divisions, patents of addition, reissues, renewals,
extensions, improvement patents and/or foreign counterparts thereof. In no event
shall JT Patents be deemed to include the Corixa Patents. The JT Patents in
existence as of the Effective Date are listed on Exhibit C.

         1.32     "[*] Antigen" shall mean that Antigen containing the nucleic
and amino acid sequences listed on Exhibit D.

         1.33     "[*] Vaccine" shall mean a Vaccine which contains all or a
portion of the [*] Antigen.

         1.34     "Licensed Patents" shall mean (i) the patents and patent
applications listed on Exhibit B-2, (ii) patents or patent applications in Japan
claiming priority of one or more patent applications of Exhibit B-2 or patent
applications filed or to be filed in the U.S. after the international filing
date, November 30, 2001, of [*] listed in Exhibit B-2, which are continuation or
continuation-in-part applications, for which priority has been claimed in the
patent applications listed in Exhibit B-2, and (iii) any other patent or patent
applications or given claims thereof owned or controlled by Corixa in Japan that
are exclusively related to [*] Vaccine during the term of this Agreement.

-----------------------------------
* Confidential treatment requested.

                                       4

<PAGE>

         1.35     "Licensed Product(s)" shall mean any in vivo administered
prophylactic and/or therapeutic that comprises at least one Antibody and any in
vivo administered prophylactic and/or therapeutic cancer Vaccine that includes
at least one (1) Antigen.

         1.36     "Net Corixa Sales" shall mean the amount invoiced by Corixa,
or its Third Party licensee(s), as applicable, for the sale or other disposition
to a Third Party of a Corixa Product, less the following deductions for amounts
actually incurred related to such sale or other disposition: (a) normal,
customary trade discounts (including volume discounts), credits and rebates and
allowances and adjustments for rejections, recalls or returns; (b) allowance for
bad debts or uncollectible amounts, provided that such amounts have been
formally designated as such in accordance with Corixa's internal accounting
procedures and provided further that such allowance shall not be applicable in
the event and to the extent any such designated amounts are ultimately collected
by Corixa or its Third Party licensee(s); and (c) freight, insurance, sales,
use, excise, value-added and similar taxes or duties imposed on the sale and
included in the gross amount charged, and government-mandated vaccine insurance
premiums. "Net Corixa Sales" shall not include the distribution of a reasonable
amount of Corixa Product solely for use in clinical trials or charitable uses,
provided that neither Corixa nor its Third Party licensee(s) receives any
compensation in any form for such use in excess of actual manufacturing,
handling and shipping costs incurred by Corixa or such licensee(s) in connection
therewith, which additional costs shall not exceed [*] of the [*]. Additionally,
"Net Corixa Sales" shall not include sales of Corixa Products between either
Corixa and its Affiliate(s) or between Corixa and its licensee(s), unless such
Affiliate(s) or licensee(s), as the case may be, are an end-user of such Corixa
Product. Any commercial use of a Corixa Product by Corixa or its Third Party
licensee(s) shall be considered a sale hereunder for accounting and royalty
purposes.

         1.37     "Net JT Sales" shall mean the amount invoiced by JT, or its
Third Party licensee(s), as applicable, for the sale or other disposition to a
Third Party of a [*] Vaccine, less the following deductions for amounts actually
incurred related to such sale or other disposition: (a) normal, customary trade
discounts (including volume discounts), credits and rebates and allowances and
adjustments for rejections, recalls or returns; (b) allowance for bad debts or
uncollectible amounts, provided that such amounts have been formally designated
as such in accordance with JT's internal accounting procedures and provided
further that such allowance shall not be applicable in the event and to the
extent any such designated amounts are ultimately collected by JT or its Third
Party licensee(s); and (c) freight, insurance, sales, use, excise, value-added
and similar taxes or duties imposed on the sale and included in the gross amount
charged, and government-mandated vaccine insurance premiums. "Net JT Sales"
shall not include the distribution of a reasonable amount of [*] Vaccine solely
for use in clinical trials or charitable uses, provided that neither JT nor its
Third Party licensee(s) receives any compensation in any form for such use in
excess of actual manufacturing, handling and shipping costs incurred by JT or
such licensee(s) in connection therewith, which additional costs shall not
exceed [*] of the [*]. Additionally, "Net JT Sales" shall not include sales of
[*] Vaccine between either JT and its Affiliate(s) or between JT and its
licensee(s), unless such Affiliate(s) or licensee(s), as the case may be, are an
end-user of such [*] Vaccine. Any commercial use of a [*] Vaccine by JT or its
Third Party licensee(s) shall be considered a sale hereunder for accounting and
royalty purposes.

-----------------------------------
* Confidential treatment requested.

                                       5

<PAGE>

         1.38     "Net Proceeds" shall have the meaning given to it in Section
3.4(a).

         1.39     "Phase 1" shall have the meaning given to it in 21 CFR
312.21(a), as it may be updated from time to time.

         1.40     "Phase 2" shall have the meaning given to it in 21 CFR
312.21(b), as it may be updated from time to time.

         1.41     "Phase 3" shall have the meaning given to it in 21 CFR
312.21(c), as it may be updated from time to time.

         1.42     "[*]" shall have the meaning given to it in Section 2.3.

         1.43     "[*]" shall have the meaning given to it in Section 2.3.

         1.44     "Results" shall have the meaning given to it in Section
2.6(a).

         1.45     "RFP" shall have the meaning given to it in Section 6.

         1.46     "Territory A" shall mean worldwide except for Europe,
Argentina, Brazil, Colombia and Territory B.

         1.47     "Territory B" shall mean the People's Republic of China and
its territories, possessions and protectorates, including Hong Kong and Macao.

         1.48     "Third Party(ies)" shall mean any party other than a party to
this Agreement or an Affiliate.

         1.49     "Third Party License" shall have the meaning given to it in
Section 2.3.

         1.50     "Vaccine" shall mean the administration of (an) antigen(s) in
any formulation or configuration, for the primary purpose and effect of
eliciting a prophylactic and/or therapeutic immune response directed directly or
indirectly to such antigen or one or more epitopes contained therein.

         1.51     "Valid Claim" shall mean a claim of an issued, unexpired
patent or a claim of a patent application, in either case included in the Corixa
Patents or Joint Research Program Patents (if any), that has not been (a) held
invalid or unenforceable by a final decision of a court or governmental agency
of competent jurisdiction, which decision is unappealable or was not appealed
within the time allowed therefor, or (b) admitted in writing to be invalid or
unenforceable by the holder(s) by reissue, disclaimer or otherwise.

         1.52     Interpretive Rules. For purposes of this Agreement, except as
otherwise expressly provided herein or unless the context otherwise requires:
(a) defined terms include the plural as well as the singular (and vice versa)
and the use of any gender shall be deemed to include the other gender; (b)
references to "Articles," "Sections" and other subdivisions and to "Schedules"

-----------------------------------
* Confidential treatment requested.

                                       6

<PAGE>

and "Exhibits" without reference to a document, are to designated Articles,
Sections and other subdivisions of, and to Schedules and Exhibits to, this
Agreement; (c) unless otherwise set forth herein, the use of the term
"including" means "including but not limited to"; and (d) the words "herein,"
"hereof," "hereunder" and other words of similar import refer to this Agreement
as a whole and not to any particular provision.

2.       LICENSE GRANTS.

         2.1 License to Corixa.

                  Subject to the terms and conditions of this Agreement, JT
hereby grants to Corixa a non-exclusive, worldwide (except for Japan), perpetual
license, with the right to grant sublicenses, under the JT Patents, solely to
research, develop, make, have made, use, have used, sell, offer for sale, have
sold, keep and import Corixa Products in the Corixa Licensed Field.

         2.2 License to JT.

                  Subject to the terms and conditions of this Agreement, Corixa
hereby grants to JT an exclusive license, with the right to grant sublicenses,
under the Corixa Know-How in existence as of the Effective Date and the Licensed
Patents (and any divisional patents or divisional applications, corrections or
extensions of the Licensed Patents), during the term hereof, solely to research,
develop, make, have made, use, have used, sell, offer for sale, have sold, keep
and import the [*] Vaccine solely in the JT Licensed Field and solely in Japan.
Subject to the terms and conditions of this Agreement, Corixa hereby grants to
JT a non-exclusive license, with the right to grant sublicenses, under the
Corixa Know-How owned or controlled by Corixa during the term hereof and any
patents covering the [*] Vaccine in Japan owned or controlled by Corixa during
the term hereof, solely to research, develop, make, have made, use, have used,
sell, offer for sale, have sold, keep and import the [*] Vaccine solely in the
JT Licensed Field and solely in Japan. Notwithstanding the foregoing, subject to
the terms and conditions of this Agreement, Corixa hereby grants to JT a
non-exclusive worldwide license to any Corixa Know-How and the Corixa Patents
which are necessary or useful for the manufacture of the [*] Vaccine solely for
sale in Japan pursuant to Section 6. Other than the limited right granted in the
immediately preceding sentence, JT shall have no rights to the [*] Vaccine
outside of Japan.

         2.3 Negotiation of Third Party License; Payment Obligations, Option to
             JT.

                  (a) In the event that Corixa [*] with any [*] for a [*],
Corixa will [*] and [*] for the [*] of a [*], in [*] unless such [*] does not
[*] or has [*]. In such case, Corixa shall provide JT with notice of the [*]
prior to [*] and Corixa shall [*] and [*] to [*] for [*] shall be [*].

                  Corixa shall, within thirty (30) calendar days of the
Effective Date provide JT with notice of the terms of any licenses in existence
as of the Effective Date (the "Existing License Terms") for intellectual
property rights required for the manufacture, use or sale of the [*] Vaccine in
Japan (the "Existing License Notice"), to the extent that (i) Corixa has the
right to reveal such terms and (ii) such existing license agreement permits
sublicensing.

-----------------------------------
* Confidential treatment requested.

                                       7

<PAGE>

                  JT shall have [*] days from the date of receipt of the [*] to
accept or reject the [*]. If Corixa does not have the right to disclose such [*]
Existing License Terms, Corixa shall make reasonable commercial efforts in good
faith to obtain approval of the Third Party licensor with respect to such
disclosure to JT. In the event Corixa is unable to obtain such approval from
such Third Party licensor despite Corixa's use of reasonable commercial efforts
and negotiations in good faith, and such Third Party licensor's technology is
used in the manufacture, use or sale of the [*] Vaccine, Corixa agrees to
consult with JT and to provide an introduction to such Third Party licensor in
connection therewith, if requested by JT.

                  Corixa hereby represents and warrants that Corixa does not
have any existing license agreements for intellectual property rights required
for the manufacture, use or sale of the [*] Vaccine which restrict or do not
permit sublicensing except for those non-exclusive license agreements identified
at Exhibit E.

                  JT may accept the Existing License Terms at any time during
the term hereof and Corixa shall grant a sublicense to JT under such terms only
if Corixa has the right to grant such sublicense. In the event Corixa is unable
to grant such sublicense, and such Third Party licensor's technology is used in
the manufacture, use or sale of the [*] Vaccine, Corixa agrees to consult with
JT and to provide an introduction to such Third Party licensor in connection
therewith, if requested by JT. If JT rejects the [*] or fails to notify Corixa
that it accepts such terms within the [*]day period, Corixa shall have no
further obligation to provide JT a sublicense based on such terms and shall be
free [*]. In the event that JT accepts the [*] or the Existing License Terms,
then JT shall pay (i) [*] of the aggregate amount of any cash payments,
including milestone payments, other than royalty payments, required under the
Third Party Licenses entered into after the Initial Agreement Effective Date;
(ii) all royalties due to the Third Party licensor based on sales of the [*]
Vaccine in Japan and (iii) [*] of Corixa's actual out-of-pocket costs paid to a
Third Party licensor, or reasonably incurred in connection with such Third Party
License, including external legal fees and other transaction costs, including
reasonable travel and lodging expenses, as set forth in the notice given from
Corixa to JT before JT accepts the terms. Corixa and JT shall enter into a
written sublicense under such Third Party License incorporating such terms
(provided that Corixa shall not impose an additional mark-up on the amounts that
JT is required to pay thereunder), and JT shall not have any other monetary
obligations other than as provided above. In the event Corixa [*] from [*]
despite [*], Corixa agrees to consult with JT and to provide an introduction
directly between JT and such Third Party in connection therewith, if requested
by JT.

                  (b) Subject to the terms and conditions of this Agreement,
Corixa hereby grants to JT an option to have Corixa supply adjuvants owned or
solely developed by Corixa to JT. Upon notice from JT to Corixa to exercise the
option, the parties shall in good faith negotiate the terms and payment of a
transfer price and a royalty to be due to Corixa under such adjuvant supply and
license agreement. For the Leishmania Elongation Initiation Factor, known as
LeIF, and other adjuvants, if any, claimed in the patents and patent
applications listed on Exhibit A-1 of the Initial Agreement, such royalty shall
be [*] of Net JT Sales. For all other adjuvants, the royalty or transfer price
will be negotiated between the parties; provided, however, that the terms of the

-----------------------------------
* Confidential treatment requested.

                                       8

<PAGE>

license agreement between Corixa and JT with respect to such adjuvants shall be
substantially consistent with terms granted by Corixa to third parties for such
adjuvant.

                  Subject to the terms and conditions of this Agreement, Corixa
hereby grants to JT an option to receive a license or sublicense to the
microspheres owned, developed or in-licensed by Corixa to JT. Upon notice from
JT to Corixa to exercise such option, Corixa shall, to the extent that it has
the right to grant such microsphere license or sublicense, do so and JT shall
pay Corixa the amount that Corixa must pay with respect to such microsphere
license or sublicense without an additional mark-up. For the avoidance of doubt,
no rights to any adjuvant (except as provided in this Section 2.3(b)) or
microsphere are granted herein. For any adjuvants or microsphere supplied by
Corixa to JT, JT shall only be permitted to use such adjuvant or microsphere in
connection with the [*] Vaccine and only for sale in Japan.

         2.4 No Other Rights Granted by JT.

                  As between JT and Corixa, JT is the sole owner of the JT
Patents and, except as provided in Section 2.1 above, JT grants to Corixa no
rights in any JT Patents or any other intellectual property rights owned by or
licensed to JT.

         2.5 No Other Rights Granted by Corixa.

                  As between Corixa and JT, Corixa is the sole owner of the
Corixa Intellectual Property and, except as provided in Sections 2.2 and 2.3
above, Corixa grants to JT no rights in any Corixa Intellectual Property or any
other intellectual property rights owned by or licensed to Corixa and any
licenses and sublicenses granted to JT under or pursuant to the Initial
Agreement are hereby terminated and of no further force or effect. Except as
provided in Section 2.2 above, JT shall immediately cease to use any
intellectual property rights previously licensed or sublicensed to it under or
pursuant to the Initial Agreement.

         2.6 Ownership of Results of Initial Agreement Activities.

                  (a) As between the parties, all right title and interest to
the Licensed Products, Corixa Products, Corixa Patents, the Joint Research
Program Patents, Joint Inventions and Corixa Know-How, research and development
plans, regulatory documents (including clinical data package(s)) and any and all
research material generated in the course of performing the Initial Agreement
(together, "Results"), shall be the sole and exclusive property of and owned by
Corixa, including the physical copies, samples or other embodiments thereof as
well as any and all intellectual property rights therein. Subject to the license
granted pursuant to Section 2.2, JT hereby assigns and agrees to assign to
Corixa and its successors and assigns all of JT's intellectual property rights
in any such Results.

                  (b) JT shall, within thirty (30) days of the Effective Date,
document, on behalf of, and in a manner reasonably requested by, Corixa, any and
all the documents received by JT from Corixa or Results which were made by or on
behalf of JT or are in JT's possession or control and turn over all such
documentation and any samples to Corixa, and otherwise disclose to Corixa all
writings, samples, inventions and developments made by or for JT (solely, or
with Corixa or a

-----------------------------------
* Confidential treatment requested.

                                       9

<PAGE>

Third Party) which are owned by or required to be assigned to Corixa pursuant to
the foregoing. Notwithstanding the foregoing, JT may retain a copy of the
Results for the sole purpose of exercising its license pursuant to Section 2.2.
The foregoing provision shall be subject to JT's confidentiality obligations
owing to the researchers in academia listed on Schedule 2.6(b); provided,
however, that upon Corixa's reasonable request, JT shall use commercially
reasonable efforts to obtain the consent of any such researcher to disclose such
researcher's confidential information to Corixa.

                  (c) JT shall and shall use its reasonable commercial efforts
to cause its employees, consultants and contractors to execute and deliver to
Corixa, without further compensation to either JT or any such employee,
consultant or contractor, any and all applications, oaths, declarations,
affidavits, waivers, powers of attorney, assignments and other documents and
instruments as shall be reasonably requested by Corixa to obtain, perfect,
transfer, secure or enforce any of the aforementioned rights in any jurisdiction
in the world. JT shall assist Corixa, and use its reasonable commercial efforts
to cause its employees, consultants and contractors to assist Corixa, in every
reasonable and proper way (including appearing as a witness to provide
testimony), entirely at Corixa's expense and for Corixa's benefit, in connection
with prosecuting, securing, maintaining, enforcing and defending any Results and
the intellectual property rights therein.

         2.7 Supply of Research Reagents. Upon written request of JT, Corixa
shall make available reasonable quantities of [*] Vaccine research reagents for
JT's research purposes provided (i) Corixa has excess supply available; (ii) the
parties hereto can agree on reasonable compensation for and other terms related
to the supply of such materials after negotiating such terms in good faith; and
(iii) the supply is not claimed by a Third Party with previously existing rights
thereto and Corixa does not have a reasonable expectation of future need of such
supply in connection with the [*] Vaccine development plan.

3.       UPFRONT, MILESTONE AND NET PROCEEDS PAYMENTS.

         Subject to Section 4.6, Corixa shall make the following payments to JT
under this Agreement in U.S. Dollars by wire transfer of immediately available
funds:

         3.1 Upfront Consideration. The amount of [*] shall be paid by Corixa to
JT on or before February 7, 2003.

         3.2 Corixa Milestone Payments. In addition to the amounts payable
pursuant to Section 3.1 above, Corixa shall pay JT the following milestone
payments, payable on only the first [*] Vaccine to meet such milestone,
regardless of whether any such milestone is achieved by Corixa or its licensee,
within thirty (30) calendar days of achievement of each of the following
milestones, which payment shall include Corixa's notice of achievement of such
milestone if not previously sent by Corixa to JT.

-----------------------------------
* Confidential treatment requested.

                                       10

<PAGE>

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------
                             MILESTONE                                    PAYMENT (U.S.$)
--------------------------------------------------------------------------------------------
<S>                                                                       <C>
(i)  [*] of the [*] clinical trial in the U.S. of the [*]                       [*]
Vaccine.
--------------------------------------------------------------------------------------------
(ii)  [*] of the first [*] clinical trial in the U.S. of the [*]                [*]
Vaccine.
--------------------------------------------------------------------------------------------
(iii)  [*] of the first [*] clinical trial in the U.S. of the [*]               [*]
Vaccine.
--------------------------------------------------------------------------------------------
(iv)  [*] of a [*] in the U.S. of the [*] Vaccine.                              [*]
--------------------------------------------------------------------------------------------
(v)  [*] in the U.S. of the [*] Vaccine.                                        [*]
--------------------------------------------------------------------------------------------
</TABLE>

In the event that a later milestone is achieved and a prior milestone has not
been met, such unpaid prior milestones shall be paid on such achievement of the
later milestone.

         3.3 JT Milestone Payment. JT shall pay Corixa [*] within [*] days after
[*] of the [*] Vaccine regardless of whether JT markets such [*] Vaccine or
enters into a license agreement with a Third Party. In the event that JT fails
to make the payment required by this Section 3.3, Corixa's sole remedy shall be,
at Corixa's sole discretion, to terminate the license rights granted to JT under
Section 2.2 hereof, in which case the remainder of this Agreement shall remain
in full force and effect, other than Sections 5.3, 7.1 (with respect to JT's
rights after the date Corixa terminates the license herein, but not including
amounts owed by JT to Corixa prior to such date), 8.2 and 13.6. Subject to the
terms and conditions of this Agreement, JT hereby grants to Corixa a
non-exclusive, perpetual license, with the right to grant sublicenses, under the
JT Patents, solely to research, make, have made, use, have used, sell, offer for
sale, have sold, keep and import Corixa Products in the Corixa Licensed Field in
Japan in the event that JT fails to make the payments required by this Section
3.3.

         3.4 Corixa Net Proceeds Payments.

                  (a) To the extent that Corixa or JT receives [*] or [*]
payments (whether or not referred to by such terms) from a licensee of the [*]
Vaccine, such fees shall be considered net proceeds ("Net Proceeds"). Any
payments received from such a licensee by Corixa or JT [*] funds, [*] or [*] or
other payments related to [*] of products shall not be considered Net Proceeds,
as that term is used herein. Corixa will pay a percentage of Net Proceeds to JT
on payments actually received from its licensees according to the following
schedule:

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------
                                                                              PERCENT OF NET PROCEEDS SHARED
                      LICENSE AGREEMENT TERMS                                            WITH JT
--------------------------------------------------------------------------------------------------------------
<S>                                                                           <C>
(i)  For license agreements covering Territory [*] entered into                            [*]%
prior to the [*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       11

<PAGE>

<TABLE>
--------------------------------------------------------------------------------------------------------------
<S>                                                                           <C>
(ii) For license agreements covering Territory [*] entered into                            [*]%
prior to the [*] of [*] Vaccine [*] clinical trials, but after the
[*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
(iii)  For license agreements covering Territory [*] entered into                          [*]%
after the [*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
(iv)  For license agreements covering Territory [*] entered into                           [*]%
prior to the [*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
(v) For license agreements covering Territory [*] entered into                             [*]%
prior to the [*] of [*] Vaccine [*] clinical trials, but after the
[*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
(vi)  For license agreements covering Territory [*] entered into                           [*]%
after the [*] of [*] Vaccine [*] clinical trials.
--------------------------------------------------------------------------------------------------------------
</TABLE>

                  (b) Notwithstanding the foregoing, a Net Proceeds payment
under this Section 3.4 shall only be due if, and to the extent that, the amount
that would be payable in the aggregate under this Section 3.4 is greater than
any amounts already paid under Section 3.2. For example, if [*] has been paid by
Corixa to JT under Section 3.2 above for [*] the first [*] clinical trial (but
further milestone payments have not been made) and Corixa enters into a license
agreement covering Territory [*] after the [*] of [*] clinical trials and prior
to the commencement of [*] clinical trials and Corixa receives a milestone
payment from its licensee of [*], Corixa would be required to make a payment of
[*] to JT following receipt of the milestone payment from the Corixa licensee
([*] of [*] is equal to [*] minus the [*] already paid leaves [*] payable to
JT). The payments described in this Section 3.4 shall be made within thirty (30)
calendar days of Corixa's receipt of the Net Proceeds but in no case later than
with the payment of the next milestone payments described in Section 3.2 above.
In the event that an overpayment of the amounts due to JT under this Section 3.4
occurs, such amount shall be due to Corixa within [*] calendar days following
written notice to JT describing such overpayment; provided that no such refund
shall be due until after the earlier of (i)[*] in the United States of the first
[*] Vaccine or (ii) the expiration or earlier termination of this Agreement. The
upfront consideration described at Section 3.1 shall not be creditable against
Net Proceeds.

         3.5 JT Net Proceeds Payments. JT will pay [*] of Net Proceeds received
from any JT sublicensee of the [*] Vaccine to Corixa within [*] calendar days of
receiving payments from its sublicensees.

4.       ROYALTY PAYMENTS.

         4.1 Royalties for [*] Vaccine.

                  (a) For sales by Corixa, or a Third Party licensee of Corixa
(other than JT), of any [*] Vaccine, Corixa shall pay to JT royalties on Net
Corixa Sales quarterly as follows:

-----------------------------------
* Confidential treatment requested.

                                       12

<PAGE>

<TABLE>
<CAPTION>
--------------------------------------------------------
LOCATION OF SALE OF [*] VACCINE             ROYALTY
--------------------------------------------------------
<S>                                         <C>
Territory [*] (excluding Japan)               [*]
--------------------------------------------------------
Territory [*]                                 [*]
--------------------------------------------------------
</TABLE>

                  (b) For sales by JT, or a Third Party licensee of JT (other
than Corixa), of any [*] Vaccine, JT shall pay to Corixa a [*] royalty on Net JT
Sales quarterly.

         4.2 Royalties for Corixa Products (other than [*] Vaccine). For sales
by Corixa, or a Third Party licensee of Corixa (other than JT), of any product
that incorporates a Corixa Product (other than the [*] Vaccine), Corixa shall
pay to JT royalties on Net Corixa Sales quarterly as follows:

<TABLE>
<CAPTION>
--------------------------------------------------------
LOCATION OF SALE                          ROYALTY
--------------------------------------------------------
<S>                                       <C>
 Territory [*]                              [*]
--------------------------------------------------------
 Territory [*]                              [*]
--------------------------------------------------------
</TABLE>

         4.3 Royalty Reduction in Event of No Valid Claim.

                  (a) In the event any [*] Vaccine sold or otherwise distributed
by JT or its Third Party licensee(s) is not covered by one (1) or more Valid
Claim(s) in Japan at the time of such sale or distribution, then the amounts
payable by JT to Corixa in connection with the sale or distribution of such [*]
Vaccine in Japan under this Section 4 shall be reduced by [*] until such time as
there exists at least one (1) Valid Claim covering such [*] Vaccine in Japan.
JT's obligation to make royalty payments in connection with [*] Vaccine not
covered by one (1) or more Valid Claim(s) in Japan at the time of such sale or
distribution, shall exist only during the [*]year period following the date of
first commercial sale or distribution in Japan; provided, however, that at such
time as there exists at least one (1) Valid Claim covering the [*] Vaccine in
Japan, whether during or following such [*]year period, JT shall then be
obligated to pay the full amounts applicable to the [*] Vaccine covered by one
(1) or more Valid Claim(s) in Japan at the time of such sale or distribution.

                  (b) In the event any Corixa Product sold or otherwise
distributed by Corixa or its Third Party licensee(s) is not covered by one (1)
or more Valid Claim(s) in the country and at the time of such sale or
distribution, then the amounts payable by Corixa to JT in connection with the
sale or distribution of such Corixa Product in such country under this Section 4
shall be reduced by [*] until such time as there exists at least one (1) Valid
Claim covering such Corixa Product in the country where it is sold or otherwise
distributed. Corixa's obligation to make royalty payments in connection with
Corixa Products not covered by one (1) or more Valid Claim(s) in the country and
at the time of such sale or distribution, shall exist only during the [*]year
period following the date of first commercial sale or distribution in such
country; provided, however, that at such time as there exists at least one (1)
Valid Claim covering the Corixa Products in the country where it is sold or
otherwise distributed, whether during or following such [*]-year period, Corixa
shall then be obligated to pay the full amounts applicable

-----------------------------------
* Confidential treatment requested.

                                       13

<PAGE>

to the Corixa Products covered by one (1) or more Valid Claim(s) in such country
at the time of such sale or distribution.

         4.4 Royalty Term; Single Royalty. Notwithstanding anything to the
contrary, royalties shall be earned and paid between the parties hereto until
the later of (i) [*] years after the first commercial sale of a product or (ii)
expiration of the last Valid Claim covering such product under any of the
Licensed Patents in the country of sale. Only one applicable royalty payment
shall be due on the sale of each Corixa Product, including any [*] Vaccine.

         4.5 Currency. All amounts payable under this Agreement shall be payable
in United States Dollars, by wire transfer of immediately available funds to a
bank account designated by the receiving party, at the receiving party's option.
Monthly sales amounts shall be translated into U.S. Dollars by using an average
rate of exchange. This average shall be computed using the rate of exchange
quoted under Foreign Exchange in the Wall Street Journal as of the end of the
current month plus the rate as of the end of the prior month and dividing by two
(2).

         4.6 Withholding Taxes. If any law or regulation in any country requires
the withholding of any taxes due on payments to be remitted to the other party
under this Agreement, such taxes shall be deducted from the amounts paid. If the
taxes are deducted from the amounts paid, the withholding party or its licensees
or sublicensees shall promptly deliver proof of payment of all such taxes,
levies and other charges, together with copies of all communications from or
with such governmental authority with respect thereto and shall provide any
reasonable assistance or cooperation which may be requested by the other party
in connection with any efforts such party makes to obtain a credit for such
taxes. Corixa and JT acknowledge and agree that a certification on tax payment
issued by the Japanese or United States tax authorities (to avoid double
taxation with respect to an amount paid hereunder) shall be deemed as reasonable
proof of such payment by the respective parties.

         4.7 Currency Transfer Restrictions. If in any payment or transfer of
funds out of a country is prohibited by law or regulation, the parties hereto
shall confer regarding the terms and conditions on which Corixa Products shall
be sold in such countries, including the possibility of payment of royalties to
the party which would receive such payments in local currency to a bank account
in such country or the renegotiation of royalties for such sales, and in the
absence of any other agreement by the parties, such funds shall be [*].

         4.8 Royalty Payments Upon Termination. If this Agreement and the rights
and licenses granted to Corixa in Section 2 hereof, are terminated in accordance
with Section 14 with respect to all or some of the Corixa Products, Corixa shall
continue to pay JT all amounts earned pursuant to this Section 4 prior to the
date of such termination and any amounts earned thereafter as a result of sales
of residual inventory of Corixa Products. In addition, Corixa shall continue to
pay to JT all amounts payable hereunder with respect to Corixa Products, if any,
with respect to which this Agreement is not terminated. If this Agreement and
the rights and licenses granted to JT in Section 2 hereof, are terminated with
respect to the [*] Vaccine, JT shall continue to pay

-----------------------------------
* Confidential treatment requested.

                                       14

<PAGE>

Corixa all amounts earned pursuant to this Section 4 prior to the date of
termination and any amounts earned thereafter as a result of sales of residual
inventory of the [*] Vaccine.

5.       REPORTS, PAYMENTS, ACCOUNTING AND DILIGENCE

         5.1 Payments and Quarterly Reports.

                  (a) Each party agrees to make written reports (consistent with
GAAP and/or its Japanese equivalent and in a format, if any, agreed to by the
parties) to the other party within forty-five (45) days after the close of each
calendar quarter during the period when payment may be due between the parties.
These reports shall show for such calendar quarter sales by such party, its
Affiliates and sublicensees or licensees of Corixa Products or [*] Vaccine, as
the case may be, details of the quantities of each type of Corixa Product sold
in each country and the country of manufacture, if different, gross revenues
from sales, trade discounts allowed and taken, Net Corixa Sales or Net JT Sales,
as the case may be, and the royalties due to the other party under this
Agreement. Concurrently with the making of such report, each party shall make
payment to the other party of all amounts payable for the period covered by such
report.

                  (b) Each party shall notify the other in writing within thirty
(30) days of achievement of a milestone which triggers a payment obligation to
the other party. The notification shall include the amounts payable for the
period covered by such milestone.

         5.2 Accounting. Each party agrees to keep clear, accurate and complete
records, all in a format, if any, agreed by the parties in accordance with GAAP
and/or its Japanese equivalent, for a period of at least three (3) years for
each reporting period in which sales occur showing the manufacturing, sales, use
and other disposition of Corixa Products in sufficient detail to enable amounts
payable or expenses reimbursable hereunder to be determined, and further agrees
to permit its books and records to be examined by an independent accounting firm
selected by the other party and reasonably satisfactory to the party to be
audited, and that is bound in confidence to disclose only evidence of
noncompliance, from time-to-time to the extent necessary, but not more than once
a year. Each party shall have the right, at its sole expense except as
hereinafter provided, through a certified public accountant reasonably
acceptable to the other party, and following reasonable notice, to examine such
records during regular business hours during the life of the other party's
payment obligations under this Agreement and for three (3) years thereafter;
provided, however, that such examination shall not (i) be of records for more
than the prior three (3) years, (ii) take place more often than once a year, and
(iii) cover any records which date prior to the date of the last examination,
and provided further that such accountants shall report to the requesting party
only as to the accuracy of the royalty statements and payments. Copies of such
reports shall be supplied to the audited party. In the event the report
demonstrates an underpayment, the underpaying party shall pay the amount of such
underpayment immediately upon request of the other party and to the extent such
underpayment is more than [*] for the audited period, shall reimburse the
requesting party for the expense of the audit. If a party has overpaid the other
party, the overpaying party may deduct such overpayments from future amounts
owed to the other party.

-----------------------------------
* Confidential treatment requested.

                                       15

<PAGE>

         5.3 Annual Reports and Diligence in Research and Commercial
             Development.

                  (a) Each party agrees to make written reports (in a format to
be agreed to by the parties) to the other party within forty-five (45) days
after the close of each calendar year during the term of this Agreement. Such
annual report will describe in reasonable detail the reporting party's current
stage of development or commercialization, as applicable, for the [*] Vaccine
and shall set forth the progress made, any material obstacles to progress that
have been identified and the results of any research, including the subject(s)
and schedule(s) of any ongoing research, performed by or on behalf of or jointly
with a third party by such party related to the [*] Vaccine. In addition to the
foregoing, upon JT's reasonable request or to the extent Corixa deems necessary,
but no more than quarterly, Corixa shall provide information relating to any
research that has been completed including data and other reasonable details.

                  (b) JT or its sublicensee shall [*], no later than three [*]
after an approval by the FDA of the [*] Vaccine in the U.S., obtain the approval
from the Health, Labor and Welfare Ministry of Japan (the "Health Ministry") to
sell [*] Vaccine in Japan provided, however, that the date for such approval to
sell the [*] Vaccine may be extended, in the event of delays beyond the
reasonable control of JT or its sublicensees for regulatory reasons or problems
arising in connection with [*] Vaccine clinical trials in Japan which are unique
to the conduct of such trials in Japan (including in the event that the
manufacture, use or sale of the [*] Vaccine results in the infringement of Third
Party intellectual property rights and a failure of suppliers to provide
necessary materials, in each case if beyond the reasonable control of JT). Once
approved in Japan, JT or its sublicensee will thereafter [*] product to commence
and continue the subsequent marketing and commercialization of [*] Vaccine in
Japan. Corixa shall reasonably cooperate with any such efforts including,
without limitation, through promptly responding in sufficient detail to JT's
inquiries concerning the above reports and the data received by JT under Section
8.1. JT or its sublicensee shall [*] make first commercial sale of the [*]
Vaccine in Japan within [*] following approval by the FDA in the U.S..

                  (c) If JT or its sublicensees has not made first commercial
sale of the [*] Vaccine in Japan within the [*] period set forth in Section
5.3(b), subject to 10.2 hereof, Corixa's sole right or remedy, unless JT is in
breach of any other provision of this Agreement, shall be to [*] Subject to the
terms and conditions of this Agreement, JT hereby grants to Corixa a
non-exclusive, perpetual license, with the right to grant sublicenses, under the
JT Patents, solely to research, make, have made, use, have used, sell, offer for
sale, have sold, keep and import Corixa Products in the Corixa Licensed Field in
Japan in the event that [*].

         5.4 Confidentiality of Reports. Each party agrees that the information
set forth in (a) the reports required by Sections 5.1 and 5.3, and (b) the
records subject to examination under Section 5.2, shall be subject to Section 8
hereof and maintained in confidence by the receiving party and any independent
accounting firm selected by such party, shall not be used by such party or such
accounting firm for any purpose other than verification of the performance by
the other party of its obligations hereunder, and shall not be disclosed by the
receiving party or such accounting firm to any other person except for purposes
of enforcing this Agreement.

-----------------------------------
* Confidential treatment requested.

                                       16

<PAGE>

6.       MANUFACTURING; SUPPLY.

         JT shall be responsible for all obligations relating to the manufacture
of [*] Vaccine in Japan. In the event that JT wishes to purchase [*] Vaccine
from Corixa, JT shall notify Corixa in a written request for proposal ("RFP")
and shall set forth the types and amounts of [*] Vaccine that JT desires to
obtain. Thereupon, Corixa shall respond to the RFP within [*] from receipt of
the RFP. If Corixa currently manufactures the [*] Vaccine and JT wishes that
Corixa be its supplier of [*] Vaccine for Japan, JT and Corixa shall negotiate
in good faith a manufacturing and supply agreement therefor, the terms of which
shall be substantially consistent with other Corixa manufacturing and supply
agreements in comparable circumstances entered into no more than [*] of the date
of JT's RFP (or which will otherwise be commercially reasonable if there are no
such comparable agreements). If Corixa is not the manufacturer for the [*]
Vaccine and JT wishes that Corixa be its supplier of [*] Vaccine for Japan,
Corixa may at its option either supply [*] Vaccine to JT itself on terms to be
agreed by the parties, arrange for the supply to JT by a Third Party or license
to JT all of Corixa's manufacturing know-how and other technologies including
patents and patent applications necessary or useful for and directly related to
the manufacture of the [*] Vaccine, in each case on terms to be negotiated by
the parties in good faith.

7.       PATENTS; PROSECUTION AND LITIGATION.

         7.1 As between the parties, Corixa shall have complete control and
discretion regarding any prosecution or maintenance of the Corixa Patents
outside of Japan. Corixa shall have the first right (but no obligation) to
prosecute and maintain all Licensed Patents in Japan as provided in this Section
7. If Corixa elects not to maintain or prosecute the Licensed Patents in Japan,
JT may elect to do so at JT's sole expense to the extent necessary to protect
its rights hereunder. Each party agrees to keep the other party promptly and
fully informed of the course of patent prosecution or other proceedings relating
to the Licensed Patents in Japan, including by providing the other party with
copies of substantive communications, search reports and Third Party
observations submitted to or received from patent offices. Each party shall hold
all information disclosed to it under this Section as confidential information
under Section 8. JT shall reimburse Corixa for all reasonable and documented
costs incurred by Corixa in connection with the filing, prosecution and
maintenance of the Licensed Patents in Japan, including (i) [*] of such cost for
international patent application(s) (i.e., PCT); and (ii) [*] of such cost for
transferring such international patent application(s) to the national stage in
Japan, payable within [*] following a request for reimbursement from Corixa;
provided however, in the event that antigens other than the [*] Antigen are
claimed in a Licensed Patent, JT shall reimburse Corixa the amount equal to [*]
of the aggregate amount of such costs related to such Licensed Patent. Except as
otherwise provided in this Agreement, Corixa shall be responsible for all costs
and expenses in connection with all Corixa Patents, including the Corixa
Patents, outside of Japan. All expenses reimbursed by JT pursuant to this
Section shall be obligations that are separate and apart from other payment
obligations described in this Agreement and shall be invoiced and paid
separately, with no right of offset. Notwithstanding anything herein to the
contrary, JT shall not be responsible for any patent costs incurred under the
Initial Agreement after November 3, 2002

-----------------------------------
* Confidential treatment requested.

                                       17

<PAGE>

and Corixa shall be responsible for all such costs incurred beginning November
4, 2002 through and including December 18, 2002.

         7.2 JT shall have the right and the obligation to prosecute and
maintain all JT Patents as provided in this Section 7 and shall do so in a
timely manner. JT agrees to keep Corixa promptly and fully informed of the
course of patent prosecution or other proceedings, including by providing Corixa
with copies of substantive communications, search reports and Third Party
observations submitted to or received from patent offices. JT shall provide such
patent consultation to Corixa at no cost to Corixa. Corixa shall hold all
information disclosed to it under this Section as confidential information under
Section 8. In the event Corixa acquires a license in Japan under the JT patents
pursuant to Section 3.3, 5.3(c) or 14.6(b), JT shall thereafter have the right
to abandon any of the JT patents and in such case Corixa shall have the right
but not the obligation to prosecute and maintain all such JT Patents in JT's
name, and JT shall reasonably assist Corixa with such prosecution and
maintenance, provided that Corixa shall reimburse JT for all reasonable [*]
expenses incurred by JT in providing such assistance. JT shall give Corixa at
least [*] notice of its intent to abandon a JT Patent prior to taking any action
to abandon such JT Patent. For the avoidance of doubt, such abandoned patents
shall be deemed to be JT Patents.

         7.3 (a) In the event of the initiation of any suit by a Third Party
against JT for patent infringement with respect to the [*] Vaccine, JT shall
promptly notify Corixa in writing and Corixa shall be entitled (but not
obligated) to defend any such suit at its own expense. In the event that Corixa
elects not to defend JT against a suit related to the [*] Vaccine, JT may, at
its own expense, defend such suit to the extent necessary to protect the rights
granted to JT hereunder. Whichever party defends such suit shall keep the other
party reasonably informed of developments with respect thereto (including any
settlement discussions) and shall be entitled to keep any amount awarded by a
court or arbitrator relating to such suit. Each party shall have the right but
not the obligation to participate in the defense of such suit, and in such event
the participating party shall do so at its own expense. If a party does not
agree in writing with any settlement effected by the other party, the
non-consenting party shall not be required to pay any amount of such settlement
and instead shall have the right to continue to maintain such suit against such
Third Party at its own expense solely with respect to its rights under this
Agreement. The parties shall keep one another informed of the status of their
respective activities regarding any litigation or settlement concerning any suit
under this Section 7.3.

         (b)      In the event of the initiation of any suit in Japan by a Third
Party against Corixa for patent infringement relating to the [*] Vaccine, Corixa
shall promptly notify JT in writing Corixa shall keep JT reasonably informed of
developments with respect thereto (including any settlement discussions) and
shall be entitled to keep any amount awarded by a court or arbitrator relating
to such suit. JT shall have the right but not the obligation to participate in
the defense of such suit, and in such event shall do so at its own expense.
Corixa shall take JT's comments thereon into consideration and obtain JT's prior
written approval (which shall not be unreasonably withheld) insofar that any
settlement may materially impact upon JT's rights hereunder. At the time when JT
decides to start clinical trials in Japan and JT asks Corixa in writing to
furnish information about any suits other than in Japan against Corixa for
patent

-----------------------------------
* Confidential treatment requested.

                                       18

<PAGE>

infringement relating to the [*] Vaccine, Corixa shall provide the
information with respect to development and/or results of any law suits brought
by a Third Party against Corixa for patent infringement outside of Japan
relating to the [*] Vaccine to the extent that such disclosure will not, in
Corixa's reasonable discretion, adversely affect any pending litigation or
Corixa's business.

         7.4 In the event that JT becomes aware of actual or threatened
infringement of a Corixa Patent, JT shall promptly notify Corixa in writing. In
the event that Corixa becomes aware of actual or threatened infringement of a JT
Patent, Corixa shall promptly notify JT in writing. Corixa shall have the first
right (but not the obligation) to bring any action relating to an actual or
threatened infringement of a Corixa Patent, including the [*] Vaccine at its own
expense. In the event that Corixa elects not to bring a suit related to the
actual or threatened infringement of the [*] Vaccine, JT may, at its own
expense, bring such suit. JT shall have the first right (but not the obligation)
to bring any action relating to an actual or threatened infringement of a JT
Patent, at its own expense. In the event that JT elects not to bring a suit
related to the actual or threatened infringement of the JT Patent, Corixa may,
at its own expense, bring such suit. Whichever party brings a suit hereunder
shall be entitled to keep any amount awarded by a court or arbitrator relating
to such suit. The parties shall keep one another informed of the status of their
respective activities regarding any litigation or settlement concerning any suit
under this Section 7.4.

         7.5 NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, OTHER THAN THOSE EXPRESSLY SET FORTH IN 13 BELOW, WITH RESPECT TO THE
JT PATENTS, CORIXA PRODUCTS, CORIXA PATENTS, OR CORIXA KNOW-HOW, INCLUDING ANY
WARRANTY OF NONINFRINGEMENT, PATENTABILITY, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE.

8.       DISCLOSURE; CONFIDENTIALITY; PUBLICITY; PUBLICATIONS.

         8.1 Disclosure of Inventions. During the term of this Agreement, Corixa
will furnish or cause its licensee/partner to furnish to JT (i) all of the
clinical data package(s) filed by Corixa (or its licensee/partner) with the FDA
for a BLA related to the [*] Vaccine, (ii) all other clinical data package(s)
filed by Corixa (or its licensee/partner) with the FDA related to planned or
then ongoing clinical trials and all of the proposed protocols for new clinical
studies, including subphases such as phase 2a or phase 2b, related to the [*]
Vaccine and (iii) other relevant data, related to the [*] Vaccine, and JT will
be free to use them for a filing (New Drug Application or bridging studies, as
the case may be) in Japan. Corixa shall deliver each data package (including
minutes of meetings prepared by the FDA and material written correspondence
reflecting official FDA actions, related to the [*] Vaccine) to JT within ten
(10) business days after filing it with the FDA for a BLA or to initiate the
next clinical phase. Corixa shall deliver a copy of the IND related to the [*]
Vaccine filed with the FDA within thirty (30) days of the Effective Date. After
the data package is delivered to JT, Corixa also agrees to provide JT with
subsequent meetings minutes prepared by the FDA and material written
correspondence reflecting official FDA actions. During the term of this
Agreement, JT shall promptly disclose to Corixa and/or supply

-----------------------------------
* Confidential treatment requested.

                                       19

<PAGE>

to Corixa in a timely fashion with all relevant patent applications filed and/or
controlled by JT and clinical data package(s) related to the JT Patents.

         8.2 Safety. During the term of this Agreement, each party shall
promptly inform the other party of any information that it obtains or develops
regarding the utility and safety of any Corixa Product or [*] Vaccine and shall
promptly report to the other party any confirmed information of serious or
unexpected reactions or side effects related to the utilization or medical
administration of such Corixa Product or [*] Vaccine.

         8.3 Confidential Information. During the term of this Agreement and for
[*] years thereafter, irrespective of any termination earlier than the
expiration of the term of this Agreement, Corixa and JT shall not use or reveal
or disclose to any Third Party any confidential information received from the
other party or otherwise developed by either party in the performance of
activities in furtherance of this Agreement without first obtaining the written
consent of the disclosing party, except as may be otherwise provided herein, or
as may be deemed appropriate by a party hereto in its reasonable judgment for
purposes of investigating, developing, manufacturing, using or marketing any
Corixa Product or [*] Vaccine or for securing essential or desirable
authorizations, privileges or rights from governmental agencies, or is required
to be disclosed to a governmental agency, or is necessary to file or prosecute
patent applications concerning any Corixa Product or [*] Vaccine or to carry out
any litigation concerning any Corixa Product or [*] Vaccine. This
confidentiality obligation shall not apply to such information which is or
becomes a matter of public knowledge, or is already in the possession of the
receiving party, or is disclosed to the receiving party by a Third Party having
the right to do so, or is subsequently and independently developed by employees
of the receiving party or Affiliates thereof who had no knowledge of the
confidential information disclosed. The parties shall take reasonable measures
to assure that no unauthorized use or disclosure is made by others to whom
access to such information is granted.

         8.4 Permitted Disclosures. Nothing herein shall be construed as
preventing a party hereto from disclosing any information received from the
other party hereto (the "Disclosing Party") or related to the JT Patents, the
Licensed Patents or this Agreement to any Affiliate or actual or potential
licensee or distributor of such party, provided such Affiliate or such Third
Party is bound by similar confidentiality obligations and such Affiliate or such
Third Party has undertaken in writing a similar obligation of confidentiality
with respect to the confidential information, with the Disclosing Party stated
as a third-party beneficiary thereof.

         8.5 Bankruptcy Procedures. All confidential information disclosed by
one party to the other shall remain the intellectual property of the disclosing
party. In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial or
complete control over the assets of a party to this Agreement based on the
insolvency or bankruptcy of such party, the bankrupt or insolvent party shall
promptly notify the court or other tribunal (i) that confidential information
received from the other party under this Agreement remains the property of the
other party and (ii) of the confidentiality obligations under this Agreement. In
addition, the bankrupt or insolvent party shall, to the extent permitted by law,
take all steps necessary or desirable to maintain the confidentiality of the
other party's

-----------------------------------
* Confidential treatment requested.

                                       20

<PAGE>

confidential information and to insure that the court, other tribunal or
appointee maintains such information in confidence in accordance with the terms
of this Agreement.

         8.6 Press Release. The parties to this Agreement may disclose the
nature and general terms of the Agreement in a press release following signature
after due consultation with the other party. The wording of any press release
must be agreed to by both parties in advance of its release; provided that such
agreement is not unreasonably withheld by either party. Notwithstanding the
foregoing, each party shall have the right to issue press releases immediately
and without prior consent of the other that disclose any information required by
the rules and regulations of the Securities and Exchange Commission or similar
federal, state or foreign authorities, as determined in good faith by the
disclosing party.

9.       GOVERNING LAW; ARBITRATION.

         This Agreement shall be governed by the laws of the State of New York,
USA. Prior to engaging in any formal dispute resolution with respect to any
dispute, controversy or claim arising out of or in relation to this Agreement or
the breach, termination or invalidity thereof (each, a "Dispute"), the Chief
Executive Officers of the respective parties or their designees shall attempt
for a period of not less than sixty (60) days to resolve such Dispute. Any
Dispute that cannot be settled amicably by agreement of the parties pursuant to
the preceding sentence, shall be finally settled by binding arbitration in
accordance with the arbitration rules of the American Arbitration Association
("AAA"), then in force, by one or more arbitrators appointed in accordance with
said rules, provided that the appointed arbitrators shall have appropriate
experience in the biopharmaceutical industry; provided, however, that
arbitration proceedings may not be instituted until the party alleging breach of
this Agreement by the other party has given the other party not less than sixty
(60) days notice (or in the case of non-payment fourteen (14) days notice) to
remedy any alleged breach and the other party has failed to do so. The place of
arbitration shall be New York City, New York, USA. The award rendered shall be
final and binding upon both parties. The judgment rendered by the arbitrator(s)
shall include costs of arbitration, reasonable attorneys' fees and reasonable
costs for any expert and other witnesses. The arbitrators in such proceeding may
expressly consider the amounts paid or payable pursuant to Sections 3 and 4
hereof in considering any claim of damages. Nothing in this Agreement shall be
deemed as preventing either party from seeking injunctive relief (or any other
provisional remedy) from any court having jurisdiction over the parties and the
subject matter of the dispute as necessary to protect either party's name,
proprietary information, trade secrets, know-how or any other proprietary
rights. Judgment upon the award may be entered in any court having jurisdiction,
or application may be made to such court for judicial acceptance of the award
and/or an order of enforcement as the case may be.

10.      MISCELLANEOUS.

         10.1     Trademarks.

                  (a) Subject to the terms and conditions of this Agreement,
Corixa hereby grants to JT a royalty-free, limited, nontransferable,
non-exclusive license, during the term hereof, to use and reproduce the "Powered
by Corixa" trademark in the course of distributing and promoting

                                       21

<PAGE>

the [*] Vaccine solely within the JT Licensed Field in Japan, subject to
Corixa's prior approval of the general manner of each use, in accordance with
Corixa's review and inspection from time to time. JT will submit to Corixa a
reasonably complete description of each manner of use of the "Powered by Corixa"
trademark for Corixa's review and the parties shall agree on such manner of use
and description, taking into consideration Corixa's use policy in effect at the
time and to the extent commercially reasonable and subject to the laws of Japan,
JT hereby agrees to use the "Powered by Corixa" trademark on every [*] Vaccine
vial or end user container which it distributes in accordance with Corixa's then
current trademark policy

                  (b) JT shall be responsible for the selection, registration
and maintenance of all trademarks which are employed in connection with the sale
of the [*] Vaccine in Japan and JT shall own and/or control any such trademarks,
provided that prior to selection of such trademarks, JT shall provide Corixa an
opportunity to review and comment on any such trademark and JT shall, in good
faith and a commercially reasonable manner, take Corixa's comments into
consideration in JT's selection of such trademarks. Except in connection with
the sale of the [*] Vaccine by JT in Japan, Corixa shall be responsible for the
selection, registration and maintenance of all trademarks which are employed in
connection with any Corixa Product and Corixa shall own and/or control any such
trademarks.

         10.2     Force Majeure. If the performance of any part of this
Agreement by either party, or of any obligation under this Agreement, is
prevented, restricted, interfered with or delayed by reason of any cause beyond
the reasonable control of the party liable to perform, unless conclusive
evidence to the contrary is provided, the party so affected shall, upon giving
written notice to the other party, be excused from such performance to the
extent of such prevention, restriction, interference or delay, provided that the
affected party shall use its reasonable best efforts to avoid or remove such
causes of nonperformance and shall continue performance with the utmost dispatch
whenever such causes are removed. When such circumstances arise, the parties
shall discuss what, if any, modification of the terms of this Agreement may be
required in order to arrive at an equitable solution. For the avoidance of
doubt, the parties acknowledge and agree that events of Force Majeure shall not
be limited to acts of God, but may include, without limitation, reasonably
uncontrollable regulatory reasons arising in connection with the clinical trials
of the of the [*] Vaccine in Japan which are unique to the conduct of such
trials in Japan, and other reasonably uncontrollable reasons for the
commercialization of [*] Vaccine in Japan.

         10.3     Severability.

                  (a) In the event any portion of this Agreement shall be held
illegal, void or ineffective, the remaining portions hereof shall remain in full
force and effect.

                  (b) If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.

-----------------------------------
* Confidential treatment requested.

                                       22

<PAGE>

         10.4     Entire Agreement. This Agreement and all Exhibits hereto,
entered into as of the date first written above, constitutes the entire
agreement between the parties relating to the subject matter hereof and
supersedes all previous writings and understandings except that the Confidential
Information and Non Disclosure Agreement dated December 14, 1998, as amended
January 7, 1999, shall remain in full force and effect. The parties acknowledge
and agree that the Initial Agreement is amended and restated by this Agreement
and is of no further force and effect, except as expressly provided in this
Agreement. No terms or provisions of this Agreement shall be varied or modified
by any prior or subsequent statement, conduct or act of either of the parties,
except that the parties may mutually amend this Agreement by written instruments
specifically referring to and executed in the same manner as this Agreement.

         10.5     No Implied Waiver. No right under this Agreement or breach
hereof may be waived except in writing signed by the parties. Neither the
failure of a party to require performance of any provision of this Agreement nor
the delay in enforcing any right hereunder will be construed or act as a waiver
of such party's rights to insist on performance of such provision or any other
provision or enforce any such right at some other time.

         10.6     Construction of Agreement. Each party has cooperated in the
drafting and preparation of this Agreement and no principles of construction
will be applied against either party on the basis that such party drafted this
Agreement.

         10.7     Independent Contractors. The parties are entering into this
Agreement as independent contractors and this Agreement will not be construed to
create a partnership, joint venture or employment relationship between them.
Neither party has the right to represent itself to any Third Party as an
employee or agent of the other or to enter into any agreement or commitment on
the other's behalf or in the other's name.

11.      NOTICES.

         11.1     Any notice required or permitted under this Agreement shall be
deemed given if delivered (i) personally, (ii) by facsimile transmission
(receipt verified), (iii) by registered or certified mail (return receipt
requested), postage prepaid, or (iv) sent by express courier service (receipt
verified), to the following addresses of the parties (or such other address or
addresses as a party may designate for itself by notice given pursuant hereto):

                  IF TO CORIXA:

                           Corixa Corporation
                           1124 Columbia Street, Suite 200
                           Seattle, WA 98104
                           Attention: Chief Operating Officer
                                      with a copy to General Counsel
                           Telephone: 1-206-754-5711
                           Facsimile: 1-206-754-5994

                  WITH A COPY TO:

                           Orrick, Herrington & Sutcliffe LLP

                                       23

<PAGE>

                           666 Fifth Avenue
                           New York, New York 10103
                           Attention: L. Mark Weeks
                           Telephone: 1-212-506-5205
                           Facsimile: 1-212-506-5151

                  IF TO JT:

                           Japan Tobacco Inc.
                           2-2-1, Toranomon
                           Minato-ku, Tokyo 105-8422 Japan
                           Attention: Vice President, Pharmaceutical Business
                                      Development
                           Telephone: 81-3-3582-3111
                           Facsimile: 81-3-5572-1449

                  WITH A COPY TO:

                           Holland & Knight LLP
                           195 Broadway
                           New York, New York 10007
                           Attention: Neal N. Beaton
                           Telephone: 1-212-513-3470
                           Facsimile: 1-212-385-9010

         11.2     Any notice required or permitted to be given pursuant to this
Agreement shall be effective upon receipt by Corixa or JT, as the case may be.

12.      ASSIGNMENT.

         Neither this Agreement nor any interest hereunder shall be assignable
by either party without the written consent of the other; provided, however,
that either party may assign this Agreement and all patents related to this
Agreement to any of such party's Affiliates or to any corporation or other
entity with which such party may merge or consolidate, and/or to any corporation
or other entity to which such party may transfer all or substantially all of
such party's assets related to this Agreement, without obtaining the consent of
other party. Transfer in contravention of this Section 12 shall be considered a
material breach of this Agreement pursuant to Section 14.3 below. Subject to
other provisions of this Section 12, all rights and obligations under this
Agreement and the licenses herein granted shall be binding upon and inure to the
benefit of the successors in interest of the respective parties. Any assignment
in violation of the foregoing shall be null and void.

13.      WARRANTIES, REPRESENTATIONS AND COVENANTS.

The following warranties are made as of the Effective Date:

         13.1     Each party warrants that it has the right to enter into this
Agreement, and that this Agreement is a legal and valid obligation binding upon
such party and enforceable in accordance with its terms.

                                       24

<PAGE>

         13.2     Nothing in this Agreement shall be construed as a warranty
that patents covered by this Agreement are valid or enforceable or that their
exercise will not infringe any patent rights of third parties.

         13.3     JT warrants that Exhibit C sets forth a complete list of all
JT Patents and patent applications that are owned or controlled by JT as of the
Effective Date that are necessary or useful for the rights and licenses granted
to Corixa hereunder.

         13.4     Corixa warrants that Exhibit A lists all antigens generated by
Corixa or on behalf of Corixa during the activities under the Initial Agreement,
that Exhibit B-1 lists all patents and patent applications (except for JT
Patents or JT patent applications) arising from Corixa's activities or
activities performed on behalf of Corixa under the Initial Agreement on file in
Japan and that Exhibit B-2 sets forth a complete list of all patents that are
owned or controlled by Corixa in Japan as of the Effective Date that claim the
composition of matter of or any method of using the [*] Vaccine license granted
to JT hereunder. Corixa further warrants that as of the Effective Date, it does
not own or control process patents which, to the best of its knowledge, might be
useful in connection with the manufacture of the [*] Antigen.

         13.5     The parties warrant to one another that neither of them has
any present knowledge of the existence of any pre-clinical or clinical data or
information covering any Corixa Product or [*] Vaccine which suggests that there
may exist toxicity, safety and/or efficacy concerns which may materially impair
the utility and/or safety of such Corixa Product or [*] Vaccine.

         13.6     Each party (the "Insured Party") shall maintain in full force
and effect liability insurance coverage with terms comparable to that maintained
by other similarly situated biomedical companies engaged in clinical evaluations
or at such time as a Licensed Product is being commercially distributed or sold.
Insured Party shall maintain such comprehensive general liability insurance
during the period that the Licensed Product is being commercially distributed or
sold by Insured Party or by an Affiliate, sublicensee or agent of Insured Party,
and for an additional period of ten (10) years thereafter. The amounts of
insurance coverage required under this Section 13.6 shall not be construed to
create a limit of Insured Party's liability with respect to its indemnification
obligation under Section 16 or under any other provision of this Agreement.

         13.7     To Corixa's knowledge, as of the date hereof, the
commercialization of the [*] Vaccine in Japan in the JT Licensed Field, solely
to the extent that such [*] Vaccine is covered by the Licensed Patents, would
not, if sold on the date hereof, infringe any patent rights of Third Parties of
which Corixa is aware as of the date hereof.

         13.8     LIMITED LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS
AGREEMENT OR OTHERWISE, NEITHER CORIXA NOR JT WILL BE LIABLE WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR (i) ANY INCIDENTAL OR
CONSEQUENTIAL DAMAGES OR LOST

-----------------------------------
* Confidential treatment requested.

                                       25

<PAGE>

PROFITS OR (ii) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES.

14.      TERM AND TERMINATION.

         14.1     This Agreement may not be terminated by either party except in
accordance with this Section 14.

         14.2     The term of this Agreement shall commence on the Effective
Date and, unless otherwise terminated, shall expire when neither party hereto
has any obligation to pay the other party a royalty hereunder. Upon the
expiration of this Agreement pursuant to this Section 14.2, JT shall retain a
nonexclusive, fully-paid up license to Corixa Know-How developed prior to the
Effective Date and a nonexclusive, fully-paid up license to Corixa Know-How
developed solely and owned or controlled by Corixa during the term hereof.

         14.3     If either party materially breaches any material provision of
this Agreement and if such breach is not cured within sixty (60) days (or in the
case of non-payment, fourteen (14) days) after receiving written notice from the
other party with respect to such breach, the non-breaching party shall have the
right to terminate this Agreement by giving written notice to the party in
breach, provided that such notice of termination is given within two (2) months
of the breach and prior to cure thereof. In the event that JT terminates this
Agreement pursuant to this Section 14.3 for Corixa's uncured material breach,
then at JT's option the rights and licenses granted to JT in Section 2 hereof
shall continue in full force and effect provided that all payment and reporting
obligations of JT under this Agreement also continue in full force and effect;
provided, however, notwithstanding anything to the contrary in this Agreement,
in such event JT may offset any amounts payable to Corixa under this Agreement
by the amount of damages incurred by JT that are determined to be attributable
to Corixa's material breach, provided that such determination is made between
the parties, by arbitrator(s) or a court, as applicable, in accordance with
Section 9 and is final and non-appealable. In the event that Corixa terminates
this Agreement pursuant to this Section 14.3 for JT's uncured material breach,
then at Corixa's option the rights and licenses granted to Corixa in Section 2
hereof shall continue in full force and effect provided that all payment and
reporting obligations of Corixa under this Agreement also continue in full force
and effect; provided, however, notwithstanding anything to the contrary in this
Agreement, in such event Corixa may offset any amounts payable to JT under this
Agreement by the amount of damages incurred by Corixa that are determined to be
attributable to JT's material breach, provided that such determination is made
between the parties, by arbitrator(s) or a court, as applicable, in accordance
with Section 9 and is final and non-appealable. Subject to the terms and
conditions of this Agreement, JT hereby grants to Corixa a non-exclusive,
perpetual license, with the right to grant sublicenses, under the JT Patents,
solely to research, make, have made, use, have used, sell, offer for sale, have
sold, keep and import Corixa Products in the Corixa Licensed Field in Japan in
the event that Corixa terminates this Agreement pursuant to this Section 14.3
for JT's uncured material breach.

         14.4     Either party may terminate this Agreement if, at any time, the
other party shall file in any court or agency pursuant to any statute or
regulation of the United States or of any individual state or foreign country, a
petition in bankruptcy or insolvency or for reorganization or for an arrangement
or for the appointment of a receiver or trustee of the party or of its assets,
or

                                       26

<PAGE>

if the other party proposes a written agreement of composition or extension of
its debts, or if the other party shall be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition shall not be
dismissed within sixty (60) days after the filing thereof, or if the other party
shall propose or be a party to any dissolution or liquidation, or if the other
party shall make an assignment for the benefit of creditors.

         14.5     Notwithstanding the bankruptcy of a party hereto, or the
impairment of performance by such party of its obligations under this Agreement
as a result of bankruptcy or insolvency, the non-bankrupt party shall be
entitled to retain the rights and licenses granted herein, without any further
obligations to the bankrupt party, subject to either party's right to terminate
this Agreement for reasons other than bankruptcy or insolvency as expressly
provided in this Agreement.

         14.6     (a) Corixa may terminate this Agreement upon sixty (60) days
written notice to JT in case of a breach of Section 5.3 by JT, unless JT cures
such breach prior to the expiry of said sixty (60) day period.

                  (b) JT may at any time, upon thirty (30) days prior written
notice to Corixa, terminate the license granted to JT under Section 2.2., in
which case the remainder of this Agreement shall remain in full force and
effect, other than Sections 5.3, 7.1 (with respect to JT's rights and
obligations after the date JT terminates the license herein, but not including
amounts owed by JT to Corixa prior to such date), 8.2 and 13.6 (with respect to
JT's obligation). Subject to the terms and conditions of this Agreement, JT
hereby grants to Corixa a non-exclusive, perpetual license, with the right to
grant sublicenses, under the JT Patents, solely to research, make, have made,
use, have used, sell, offer for sale, have sold, keep and import Corixa Products
in the Corixa Licensed Field in Japan in the event that JT terminates its
license hereunder pursuant to this Section 14.6(b).

15.      RIGHTS AND DUTIES UPON TERMINATION.

         15.1     Upon termination of this Agreement, each party shall have the
right to retain any sums already paid to it hereunder, and each party shall pay
all sums accrued hereunder which are then due, which, in each case, shall
include all payments under Sections 3 and 4 except to the extent such payments
may be considered and reviewed by the arbitrator(s) pursuant to Section 9
hereof.

         15.2     Expiration or early termination of this Agreement shall not
relieve either party of its obligations incurred prior to such expiration or
early termination. In addition, Sections 1, 2.1, 2.6, 4, 5.1, 5.2, 7.3,7.4, 7.6,
7.7, 8.3, 8.4, 8.5, 9, 10, 11, 13.6(a) (for so long as JT continues the sale of
[*] Vaccine and thereafter for so long as JT maintains insurance for itself
covering such sales), 13.6(b) (for so long as Corixa continues the sale of
Corixa Products and thereafter for so long as Corixa maintains insurance for
itself covering such sales), 14.3, 14.5, 15, and 16 shall survive any expiration
or early termination of this Agreement. Sections 3.4 and 3.5 shall each survive
with respect to Net Proceeds payments which accrued prior to termination or
expiration

-----------------------------------
* Confidential treatment requested.

                                       27

<PAGE>

hereof. In addition, in the event this Agreement is terminated pursuant to
Section 14.3, Sections 2 and 5.1(a) and all reporting obligations of JT under
this Agreement shall survive as provided in Section 14.3. Further, Section 7.1
shall survive any expiration or termination of this Agreement solely with
respect to the payment and reimbursement of any patent-related costs and
expenses that were incurred prior to such termination or expiration.

16.      INDEMNIFICATION.

         16.1     Subject to Section 16.2 hereof, from and after the Effective
Date, except as otherwise herein specifically provided, each of the parties
hereto shall defend, indemnify and hold harmless the other party and its
Affiliates, successors and assigns, and their respective officers, directors,
shareholders, partners and employees ("Indemnified Party"), from and against all
losses, damage, liability and expense, including legal fees, but excluding
punitive or consequential damages (including lost profits) ("Damages"), incurred
thereby or caused thereto arising out of or relating to (i) any breach or
violation of, or failure to properly perform, any covenant or agreement made by
such Indemnifying Party (as defined in Section 16.2) in this Agreement, unless
waived in writing by the Indemnified Party (as defined in Section 16.2); (ii)
any breach of any of the representations or warranties made by such Indemnifying
Party in this Agreement; or (iii) the gross negligence or willful misconduct of
the Indemnifying Party; provided, however, that this subsection (iii) shall not
apply to the extent such Damages are attributable to the gross negligence or
willful misconduct of the Indemnified Party.

         16.2     If Indemnified Party receives any written claim which it
believes is the subject of indemnity hereunder by either Corixa or JT, as the
case may be (in each case an "Indemnifying Party"), the Indemnified Party shall,
as soon as reasonably practicable after forming such belief, give notice thereof
to the Indemnifying Party, including full particulars of such claim to the
extent known to the Indemnified Party; provided, however, that the failure to
give timely notice to the Indemnifying Party as contemplated hereby shall not
release the Indemnifying Party from any liability to the Indemnified Party. The
Indemnifying Party shall have the right, by prompt notice to the Indemnified
Party, to assume the defense of such claim with counsel reasonably satisfactory
to the Indemnified Party, and at the cost of the Indemnifying Party. If the
Indemnifying Party does not so assume the defense of such claim, the Indemnified
Party may assume such defense with counsel of its choice at the sole expense of
the Indemnifying Party. If the Indemnifying Party so assumes such defense, the
Indemnified Party may participate therein through counsel of its choice, but the
cost of such counsel shall be borne solely by the Indemnified Party.

         16.3     The party not assuming the defense of any such claim shall
render all reasonable assistance to the party assuming such defense, and all
out-of-pocket costs of such assistance shall be borne solely by the Indemnifying
Party.

         16.4     No such claim shall be settled other than by the party
defending the same, and then only with the consent of the other party, which
shall not be unreasonably withheld; provided, however, that the Indemnified
Party shall have no obligation to consent to any settlement of any such claim
which imposes on the Indemnified Party any liability or obligation which cannot
be assumed and performed in full by the Indemnifying Party.

                                       28

<PAGE>

                            [Signature page follows]

                                       29

<PAGE>

         IN WITNESS WHEREOF, each of the parties hereto has caused this
Agreement to be executed by its duly authorized officer as of the date first
written above.

CORIXA CORPORATION                           JAPAN TOBACCO INC.

By: /s/ Steven Gillis                        By: /s/ Takashi Kato
    _____________________________________        ______________________________
    Steven Gillis                                Takashi Kato
    Chairman and Chief Executive Officer         Member of the Board, Executive
                                                 Vice President and President,
                                                 Pharmaceutical Division

                                       30

<PAGE>

                      EXHIBIT A TO COLLABORATION AGREEMENT

                                    ANTIGENS

<TABLE>
<CAPTION>
ANTIGEN      STATUS
<S>          <C>
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
</TABLE>

-----------------------------------
* Confidential treatment requested.

<PAGE>

<TABLE>
<S>          <C>
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       2

<PAGE>

<TABLE>
<S>          <C>
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       3

<PAGE>

<TABLE>
<S>          <C>
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
  [*]          [*]
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       4

<PAGE>

                     EXHIBIT B-1 TO COLLABORATION AGREEMENT

                                 CORIXA PATENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                      <C>
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                    Converted
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  AU              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  BR              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  CN              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  CO              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  ID              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  IL              [*]                                    Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       5

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                      <C>
    [*]                  JP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  KR              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  MX              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  NO              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  PK              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  SA              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  VE              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  ZA              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]           [*]                      ISSUED
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]           [*]                      Issued
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       6

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]           [*]                       ISSUED
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  AU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  BR              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CN              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Published
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       7

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                      <C>
    [*]                  ID              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  IL              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  KR              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  MX              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  NO              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  NZ              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  PK              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  RU              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  SA              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  SG              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  VE              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  VN              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  ZA              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  AU              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                    Converted
------------------------------------------------------------------------------------------------
    [*]                  AU              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  BR              [*]                                    Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       8

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                      <C>
    [*]                  CA              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  CN              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  CZ              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  EA              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  HU              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  IL              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  IN              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  KR              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  MX              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  NZ              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  PL              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  YU              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                    Converted
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  MY              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                    Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       9

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                     <C>
    [*]                  PK              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  TH              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]           [*]                      ISSUED
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]           [*]                      ISSUED
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                    Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                    Converted
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                    Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       10

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  CO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  MY              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CN              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CZ              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  HU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PL              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  RU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       11

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Allowed
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  AU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  BR              [*]                                     Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       12

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CN              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  CZ              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  HU              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  ID              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  IN              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  KR              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  MN              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  MX              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  NO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  NZ              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PL              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  RU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  SG              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TR              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  VN              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  YU              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                     Pending
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       13

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  CO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  MY              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  HK              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  MY              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PK              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  TH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       14

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       15

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  CA              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  EP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  JP              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  AR              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  MY              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  PK              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  TH              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  TW              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  WO              [*]                                     Published
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       16

<PAGE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
                                                       PATENT NO./ISSUE
CASE NUMBER           COUNTRY    APP. NO./FILINGDATE         DATE                 STATUS
------------------------------------------------------------------------------------------------
<S>                   <C>        <C>                   <C>                       <C>
    [*]                  US              [*]                                     Converted
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Pending
------------------------------------------------------------------------------------------------
    [*]                  US              [*]                                     Abandoned
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

                                       17

<PAGE>

                     EXHIBIT B-2 TO COLLABORATION AGREEMENT

                                LICENSED PATENTS

         The following is a complete list of Licensed Patents. All Licensed
         Patents are also "Corixa Patents", as that term is used in the
         Agreement to which this Exhibit is attached.

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------
Country             Docket Number           Serial Number/      Patent No./        Status
                                             Filing Date        Issue Date
------------------------------------------------------------------------------------------------
<S>                 <C>                     <C>                 <C>               <C>
  JP                     [*]                     [*]                              Pending
------------------------------------------------------------------------------------------------
  JP                     [*]                     [*]                              Pending
------------------------------------------------------------------------------------------------
  JP                     [*]                     [*]                              Pending
------------------------------------------------------------------------------------------------
  WO                     [*]                     [*]                              Published
------------------------------------------------------------------------------------------------
</TABLE>

-----------------------------------
* Confidential treatment requested.

<PAGE>

                      EXHIBIT C TO COLLABORATION AGREEMENT

                                   JT PATENTS

None as of the Effective Date.

<PAGE>

                      EXHIBIT D TO COLLABORATION AGREEMENT

                                   [*] ANTIGEN

[*]

AND

   [*]

-----------------------------------
* Confidential treatment requested.

<PAGE>

                                    EXHIBIT E

                  NON-EXCLUSIVE THIRD PARTY LICENSE AGREEMENTS

1)       Non-Exclusive License Agreement between Corixa Corporation and [*]
         dated [*]

2)       License Agreement between Corixa Corporation and [*] dated [*]

3)       License Agreement between Corixa Corporation and [*] dated [*] and
         amended on [*].

4)       Research Agreement between Corixa Corporation and [*] dated [*]

5)       License Agreement between Corixa Corporation and [*] dated [*]

-----------------------------------
* Confidential treatment requested.<PAGE>
                                                                   Exhibit 10.84

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

                                    AGREEMENT

         Agreement ("AGREEMENT"), effective as of April 1, 1994 ("Effective
Date"), by and between the COULTER CORPORATION, a Delaware for-profit
corporation (on its own behalf and as a successor in interest to COULTER
ELECTRONICS, INC., an Illinois corporation), having its principal place of
business at 11800 S.W. 147th Avenue, Miami, Florida 33196 ("COULTER") and the
DANA-FARBER CANCER INSTITUTE, INC., a Massachusetts not-for-profit corporation
having its principal place of business at 44 Binney Street, Boston,
Massachusetts 02115 ("DFCI").

                                   WITNESSETH:

         WHEREAS, DFCI undertakes basic biological research in order to
understand and develop strategies to address the pathogenesis of cancer and
other human diseases; and

         WHEREAS, COULTER utilizes new scientific discoveries from DFCI and
elsewhere to serve humanity by developing commercial products for use by
research scientists and for the diagnosis and treatment of diseases; and

         WHEREAS, COULTER and DFCI have a longstanding and mutually beneficial
research and development collaboration involving DFCI's Division of Tumor
Immunology under the direction of Dr. Stuart F. Schlossman as memorialized in a
series of Prior Agreements having effective dates as of July 23, 1981, March 1,
1983, April 28, 1983, and April 1,1987; and

         WHEREAS, under said collaboration, COULTER has provided funds to the
Division to support basic biological research and the Division, through the
scientific expertise of its faculty, in turn has made available to COULTER
biological reagents having potential commercial significance in laboratory
research, diagnostic and therapeutic applications; and

         WHEREAS, in the course of their collaboration, the parties have
recognized that the Prior Agreements, should be clarified, certain terms thereof
renegotiated and the process formalized by which Technologies are made available
to, and evaluated by, COULTER, all in order to better effectuate the goals of
the relationship; and

         WHEREAS, the Prior Agreements have been made subject to a Settlement
Agreement between COULTER, DFCI and the Johnson and Johnson Company; and

         WHEREAS, COULTER and DFCI believe that the public interest is best
served by continuing their research and development collaboration so that
scientific inquiry is promoted and new products having laboratory research,
diagnostic and therapeutic utility are expeditiously brought to the marketplace;
and

         WHEREAS, the legal relationships between the parties can best be
affirmed through a rescission of the Prior Agreements and the execution of a new
contract, each transaction being founded upon independent consideration the
adequacy of which is hereby acknowledged;

         NOW, THEREFORE, in consideration of the mutual covenants herein
contained and intending to be legally bound hereby, the parties hereto agree as
follows:

<PAGE>

                            ARTICLE I - Definitions

         1.1 "Affiliate" shall mean any corporation or other business entity
controlled by, controlling, or under common control with COULTER. For this
purpose "control" means direct or indirect beneficial ownership of greater than
fifty percent (50%) interest in the income or stock of such corporation or other
business.

         1.2 "Division" shall mean the Division of Tumor Immunology at DFCI.

         1.3 "Field of Use" shall mean the application(s) of a Technology to be
used by COULTER such as laboratory research, diagnostics and/or therapeutics.

         1.4 "Licensing Agreement" shall mean the contractual document attached
hereto as Appendix A which is an integral part of this AGREEMENT and which,
together with the terms hereof related to the licensing of any and all
technology between DFCI and COULTER from the Division, will memorialize such
transfer of technology between the parties.

         1.5 "Net Sales" shall mean [*]

             (a)    [*]

             (b)    [*]

             (c)    [*]

             (d)    [*]

         1.6 "Prior Agreements" shall mean those contracts between COULTER (or
its corporate predecessors) and DFCI related to financial support of research
under the direction of Dr. Schlossman in return for which COULTER would receive
intellectual property rights and tangible research properties such as, but not
limited to, cell lines and monoclonal antibodies, said agreements having
effective dates as of July 23, 1981, March 1, 1983, April 28, 1983 and April 1,
1987.

         1.7 "Program Areas" shall include [*]

         1.8 "Program Projects" shall mean research projects undertaken by
members of the Division within a Program Area as delineated in Section 3.2
hereof [*].

         1.9 "Right of First Look" shall have the meaning delineated in Section
6.4 hereof.

         1.10 "Dr. Schlossman" shall mean Dr. Stuart F. Schlossman, M.D., the
Baruj Benacerraf Professor of Medicine at the Harvard Medical School and
Dana-Farber Cancer Institute and Chief, Division of Tumor Immunology at the
Dana-Farber Cancer Institute.

         1.11 "Settlement Agreement" shall mean a contract between COULTER,
DFCI, and Johnson and Johnson Company, with an effective date of March 31, 1992
memorializing the resolution of a dispute related to inventions developed within
the Division.

         1.12 "Sublicensee" shall mean any corporation, partnership or business
organization which is not an Affiliate of COULTER, but to whom COULTER transfers
know-how, rights or products, to enable said party to sell products
incorporating Technology which COULTER has licensed from DFCI.

--------------------------------------
* Confidential treatment requested

                                      -2-
<PAGE>

         1.13 "Technology" shall mean [*].

                  ARTICLE II - Rescission of Prior Agreements

         2.1 The parties hereby rescind the Prior Agreements and substitute in
their place this AGREEMENT as of the Effective Date. The remaining financial
obligations owed to DFCI by COULTER under the Prior Agreements [*] which shall
be paid by July 1, 1994. The parties hereby acknowledge that there are no
further research support payments due under the Prior Agreements.

         2.2 Notwithstanding the foregoing Section 2.1 and as long as it pays
royalties as are herein contained, COULTER shall retain the right to make, have
made, use and sell all Technology developed within the Division which has
already been offered to, and accepted by, COULTER pursuant to one or more of the
Prior Agreements.

         2.3  (a) Except for a therapeutic Technology identified as [*] which
                  was disclosed to COULTER in 1989 and which is to be licensed
                  to a third party subject only to COULTER's rights pursuant to
                  Section 6.3 hereof, technologies developed in the Division
                  which have been made available to COULTER under the Prior
                  Agreements, but to which COULTER has not exercised its option
                  rights, shall be subject to the [*] option rights and
                  review process as contained in Subparagraph 2.3(b) hereof
                  Technologies disclosed to COULTER prior to the Effective Date
                  of the Settlement Agreement shall not be subject to the
                  Settlement Agreement.

              (b) In order to fulfill the purpose of subsection 2.3(a) hereof;
                  COULTER and Dr. Schlossman agree to inventory their records
                  and all reagents transferred between COULTER and the Division,
                  such inventory to be undertaken within six (6) months of the
                  Effective Date hereof ending on September 30, 1994. A listing
                  of any Technologies subject to Subsection 2.3(a) shall be
                  given to the Corporate Counsel for COULTER and the General
                  Counsel of DFCI. COULTER shall then have an [*]. Any licensing
                  of Technologies [*], herein provided.

             (c)  Within six (6) months of the Effective Date, COULTER shall
                  provide a list of all Technologies it has accepted under one
                  or more of the Prior Agreements, together with a brief
                  description of its commercialization efforts related thereto,
                  so that each party will have a complete documentary record of
                  prior exchanges of Technology.

                  ARTICLE III - Program Areas/Program Projects

         3.1 The parties agree that research in Program Projects will be
undertaken within Program Areas in the Division, such research to be supported
in whole or in part with funds from COULTER. COULTER financial support for
Program Projects within the Division may be supplemented only with funds from
public agencies such as the National Institutes of Health, private foundations,
not-for-profit organizations unaffiliated with commercial entities, unrestricted
institutional support from DFCI, any royalty income received by the Division
which

--------------------------------------
* Confidential treatment requested

                                      -3-
<PAGE>

Dr. Schlossman elects to direct to said Program Projects and any other funding
which COULTER, DFCI and Dr. Schlossman mutually agree in writing is an
appropriate source of support which does not give rise to conflicting
intellectual property rights with another commercial entity. Dr. Schlossman
shall use good faith efforts to direct any royalty income received by the
Division which is derived from COULTER sales to the Program Areas herein
designated.

         3.2 The Program Areas and Program Projects which are eligible for
COULTER funding within the Division are as follows:

         (a)      Program Areas - [*]

                  (1)      Program Projects -

                           [a]      [*]
                           [b]      [*]
                           [c]      [*]
                           [d]      [*]
                           [e]      [*]
                           [f]      [*]
                           [g]      [*]

         (b) Program Area - [*]

                  (1)      Program Projects -

                           [a]      [*]
                           [b]      [*]
                           [c]      [*]
                           [d]      [*]
                           [e]      [*]

         (c) Program Area - [*]

(1)      Program Projects -

                           [a]      [*]
                           [b]      [*]
                           [c]      [*]
                           [d]      [*]

         (d)      Such other Program Projects or other Program Areas as may from
                  time to time be included within the terms of this AGREEMENT by
                  mutual agreement of the parties, as manifested by written
                  amendment hereof.

--------------------------------------
* Confidential treatment requested

                                      -4-
<PAGE>

         (e)      COULTER acknowledges that rights to [*]

         3.3 Dr. Schlossman will use all reasonable efforts to develop Program
Projects within the Division as identified in Section 3.2 hereof utilizing
financial support from COULTER and further complemented by financial support as
delineated in Section 3.1 hereof. [*] Dr. Schlossman shall provide COULTER's
Director of Immunology and the General Counsel of DFCI a list of all Program
Projects for which COULTER funding is being utilized.

          3.4 Dr. Schlossman ordinarily will direct COULTER funding to a
particular Program Project for multiple years in order to maintain scientific
continuity, but in his judgement and upon discussion with representatives
designated by COULTER, he may redirect such funds to other Program Projects in
order to most effectively promote the research and development objectives of the
parties.

            ARTICLE IV - Research Funding and Provision of Reagents

         4.1 COULTER agrees to provide total annual funding to the Division in
the amount of [*], to be paid quarterly in arrears. [*] DFCI, acting through Dr.
Schlossman, agrees to accept such funding and direct its use to the support of
some or all of said Program Projects. Such funding will support research in the
Program Projects delineated in Section 3.2 for [*].

         4.2 COULTER shall [*].

         4.3 The payments made hereunder shall [*].

         4.4 Upon request by Dr. Schlossman [*] in laboratory research in the
Program Areas.

                             ARTICLE V - Reporting

         5.1 DFCI shall, through the efforts of Dr. Schlossman, provide COULTER
with a written report on a quarterly basis with respect to Program Projects
being funded by COULTER as well as a summary of findings of interest in other
Program Projects and generally of activities in Program Areas. At least once per
year, Dr. Schlossman will meet personally with COULTER representatives at the
company's headquarters in Florida to provide an oral report on such matters.

         5.2 To the extent that he or other staff members within the Division
are not otherwise obligated, Dr. Schlossman may inform COULTER in such quarterly
reports of developments within the Division but outside of the Program Areas
described in Section 3.2 hereof which may be of commercial interest to COULTER.

         5.3 Upon expiration or termination of this AGREEMENT, DFCI shall,
through the efforts of Dr. Schlossman provide COULTER's Director of Immunology
with a final report on Program Projects which have been funded by COULTER and a
summary of findings of interest in other Program Projects, and more generally,
in Program Areas. In addition, Dr. Schlossman

--------------------------------------
* Confidential treatment requested

                                      -5-
<PAGE>

shall provide an inventory of
intellectual property developed within the Division to which COULTER has rights,
or has exercised rights, pursuant to ARTICLE VI, hereof.

                   ARTICLE VI - Intellectual Property Rights

         6.1 (a) DFCI shall have [*]; provided however COULTER shall have [*].

             (b) [*]

             (c) Dr. Schlossman and other members of the Division shall [*]
                 COULTER'S investigators shall [*].

         6.2 Subject to Sections 2.3 and 3.2 hereof COULTER shall have [*]. With
respect to certain Technologies which may be developed, [*].

         6.3 If COULTER waives its rights under Section 6.2 hereof [*]. COULTER
shall acknowledge its waiver of rights in writing by executing a letter
agreement which shall be prepared by DFCI requesting such waiver. The letter
agreement shall include [*].

         6.4 With respect to any Technology which arises from Program Projects
where no COULTER funding has been utilized, [*].

         6.5 From time to time, Dr. Schlossman may identify and disclose
confidentially to COULTER additional Technologies made in the Division which are
not otherwise subject to COULTER's rights under either Section 6.2 or 6.4
hereof. DFCI may license such Technologies to COULTER either pursuant to the
terms herein delineated or such other terms as the parties may agree.

         6.6 COULTER shall have the right to sublicense Technologies licensed
hereunder subject to the approval of DFCI, such approval not to be unreasonably
withheld; except to the extent that [*]

                            ARTICLE VII - Royalties

         7.1 Subject to the provisions of Section 7.2 and 7.3 hereof, COULTER
shall pay to DFCI [*] royalty on Net Sales of Technologies, irrespective of
Field of Use, developed within the Division and offered to, and accepted by,
COULTER for commercialization subject to any [*].

         7.2 Where COULTER must obtain a license from a third party in order to
practice the subject Technology developed within the Division, either because
[*] or [*], then the royalty rate provided in Section 7.1 hereof shall be [*]
thus obligating COULTER to [*], but only to the extent that COULTER [*].

--------------------------------------
* Confidential treatment requested

                                      -6-
<PAGE>

         7.3 Royalties due DFCI from COULTER on Technologies transferred from
the Division pursuant to one or more of the Prior Agreements which are subject
to the provisions of the Settlement Agreement shall be adjusted as follows:

         (a)      [*] on annual Net Sales of all such Technologies up to [*];

         (b)      [*] on annual Net Sales of all such Technologies between [*];

         (c)      [*] on annual Net Sales of all such Technologies over [*].

                    ARTICLE VIII - Disclosure and Evaluation

         8.1 In addition to meeting the reporting requirements contained in,
ARTICLE V hereof, Dr. Schlossman or a staff member within the Division acting at
his direction, shall confidentially disclose and formally offer to COULTER
through DFCI's Office of Patent Counsel in a format substantially as prescribed
in Appendix H hereof, which is an integral part of this AGREEMENT, any
Technology to which COULTER has rights pursuant to Sections 6.2 and 6.4 hereof.
Dr. Schlossman shall also use such a disclosure format when making COULTER aware
of other potential applications for commercial development pursuant to Section
6.5 hereof. Dr. Schlossman shall convey the relevant [*] to COULTER along with
the disclosure documents.

         8.2 COULTER shall promptly acknowledge in writing to DFCI and Dr.
Schlossman receipt of the disclosure documentation and accompanying [*].

         8.3 Upon receipt of documentation and [*] from DFCI pursuant to Section
8.1, COULTER shall [*]. COULTER shall use its best efforts in completing such
preparations but in no event shall this period extend beyond [*] from the date
of receipt of documentation [*]. This initial period of up to [*] shall be used
for characterization of the [*], hereinafter the CHARACTERIZATION PERIOD. Upon
completion of the CHARACTERIZATION PERIOD, COULTER shall notify DFCI's Office of
Patent Counsel in writing in the form prescribed in Appendix C.

         8.4  (a) Upon completion of the CHARACTERIZATION PERIOD pursuant to
                  Section 8.3 hereof, COULTER shall have an additional [*] to
                  conduct its evaluation of technologies disclosed pursuant to
                  Section 6.2 hereof and exercise its [*] in writing thereon.
                  This second [*] period shall be used for, evaluation of the
                  [*], hereinafter the EVALUATION PERIOD.

              (b) Upon completion of the CHARACTERIZATION PERIOD pursuant to
                  Section 8.3 hereof, and subject to the [*] as herein provided,
                  COULTER shall have up to an additional [*] to conduct its
                  evaluation of Technologies disclosed pursuant to Section 6.4
                  hereof and [*] COULTER shall [*].

--------------------------------------
* Confidential treatment requested

                                      -7-
<PAGE>

              (c) With respect to Technologies disclosed, if at all, pursuant to
                  Section 6.5, COULTER shall have such time for evaluation and
                  licensing as the parties may mutually agree.

              (d) If COULTER elects not to obtain a license for Technologies
                  disclosed pursuant to Sections 6.2, 6.4 and 6.5, the results
                  of the CHARACTERIZATION PERIOD and EVALUATION PERIOD shall be
                  shared with DFCI to provide more features about the
                  Technologies to enable DFCI to expeditiously obtain a third
                  party licensee for the Technologies.

         8.5 Upon demonstration of good faith compliance with the diligence
requirements of this AGREEMENT, the terms specified herein may be extended upon
mutual agreement of the parties.

                           ARTICLE IX - Due Diligence

         9.1 Upon licensing a Technology developed within the Division as
hereunder provided, COULTER shall [*].

         9.2 In addition to [*], COULTER shall at minimum:

         (a)      [*]:

                  (1)      [*];

         (b)      [*]:

                  (1)      [*]

                  (2)      [*];

         (c)      [*]:

                  (1)      [*].

         9.3 COULTER shall provide annual reports to DFCI on its specific goals
and objectives for commercializing any Technology licensed from DFCI.

         9.4 [TEXT MISSING]

                    ARTICLE X - Replacement of Key Personnel

         10.1 Dr. Schlossman shall be considered a key person with respect to
this AGREEMENT. In the event that he is unable to fulfill the responsibilities
herein delineated, such as by reason of death, disability, resignation or
retirement, DFCI shall have [*] within which

--------------------------------------
* Confidential treatment requested

                                      -8-
<PAGE>

to provide a replacement. Said replacement shall be acceptable to COULTER, [*]
In the event that no replacement is designated by DFCI or accepted by COULTER.
COULTER shall have the option either to continue to fund research within the
Division under this AGREEMENT or to cease to fund research within the Division
[*] after the expiration of [*].

                  ARTICLE XI - Patent Prosecution and Expenses

         11.1 Upon disclosure to COULTER of a Technology developed within the
Division, patent counsel [*]:

         (a)      the feasibility and advisability of pursuing patent
                  prosecution;

         (b)      the selection of patent counsel;

         (c)      appropriate patent strategies; and

         (d)      such other matters as may relate to protecting the
                  intellectual property interests of COULTER and DFCI.

         Upon its agreement, COULTER shall [*]. If less than all Fields of Use
         are elected for license by COULTER, [*].

         11.2 In the event that:

         (a)      [*],

         (b)      [*], and

         (c)      [*]; then

         [*]

         11.3 Subject to the provisions of Section 11.4 hereof, patent expenses
incurred by COULTER to protect a particular Technology [*] .

         11.4 COULTER hereby agrees that the [*] in expenses it has incurred, or
will incur, for patent prosecution to protect Technologies developed within the
Division and licensed to COULTER pursuant to one or more of the Prior Agreements
or this AGREEMENT [*] COULTER shall provide to DFCI within [*] of the Effective
Date hereof a reasonable synopsis of expenses incurred for securing patent
protection related to such Technologies in order for the parties [*].

         11.5 DFCI and its employees shall reasonably assist COULTER in the
preparation, filing and prosecution of patent applications arising under this
AGREEMENT provided that [*]. Each party shall be entitled to promptly receive
copies of all relevant documents related to patent

--------------------------------------
* Confidential treatment requested

                                      -9-
<PAGE>

prosecution and maintenance irrespective of which organization takes primary
responsibility for such prosecution and maintenance.

         11.6 To the extent that patentable inventions or discoveries from
research licensed hereunder made prior to, during or subsequent to this
AGREEMENT, are developed with partial funding from the federal government and/or
other non-profit, non-commercial funding agencies, any contractual arrangements
related to such inventions or discoveries between DFCI and COULTER shall be
subject to the laws, regulations and written policies of the granting
agency(ies). DFCI shall, from time to time, make copies of such laws,
regulations and policies available to COULTER.

         11.7 DFCI [*] DFCI further [*] DFCI will notify COULTER [*].

                 ARTICLE XII - Publications and Confidentiality

         12.1 DFCI shall have the right to [*] developed in the course of
research supported hereunder, such right to include [*]. COULTER will be
furnished with a draft of any proposed publication for review prior to
publication in order to ascertain whether any patentable subject matter is
disclosed therein; for manuscripts, at least [*] prior to publication, and for
abstracts, at least [*] prior to publication. If COULTER requests that patent
protection be obtained covering subject matter disclosed in the manuscript or
abstract pursuant to the provisions of ARTICLE XI, publication may be postponed
for an additional [*].

         12.2 For the purposes of publication, promotion and commercial
development, COULTER agrees to use scientific and medical nomenclature
acceptable to DFCI to identify any materials developed by DFCI.

                      ARTICLE XIII - Term and Termination

         13.1 This AGREEMENT shall remain in full force and effect from the
Effective Date to [*] unless sooner terminated; or unless extended in accordance
with this AGREEMENT.

         13.2 In the event that either party shall default in the performance
of its obligations under this AGREEMENT and shall fail to remedy such default
within [*] for breaches of financial obligations and [*] for breaches of
non-financial obligations after written notice from the other party, the
nondefaulting party shall be entitled upon giving written notice to immediately
terminate this AGREEMENT; provided however, that if the defaulting party has
undertaken and continues to undertake, good faith efforts to cure, the
defaulting party shall be granted another [*] to cure.

         13.3 Termination of this AGREEMENT, other than for nonpayment by
COULTER, shall not affect the rights and obligations of the parties which
accrued prior to termination, including without limitation:

--------------------------------------
* Confidential treatment requested

                                      -10-
<PAGE>

         (a)      COULTER's rights [*];

         (b)      DFCI's rights to [*]; and

         (c)      COULTER's rights to review manuscripts and abstracts arising
                  from research funded by COULTER prior to termination.

         13.4 This AGREEMENT may be extended for an additional term(s) upon
mutual written agreement of the parties. COULTER agrees to provide DFCI with [*]
written notice in the event it does not seek to extend this AGREEMENT.

                             ARTICLE XIV - Notices

         14.1 Unless otherwise called for by specific provisions hereunder
reports, notices and other communications from COULTER to DFCI as provided
hereunder shall be sent to:

                  Dr. Bernard W. Janicki
                  Director for Research
                  Dana-Farber Cancer Institute
                  44 Binney Street
                  Boston, MA 02115

         with a copy to:

                  Kenneth P. Trevett, Esq.
                  General Counsel
                  Dana-Farber Cancer Institute
                  44 Binney Street
                  Boston, MA 02115

         or other individuals or addresses as shall hereafter be furnished by
         written notice to COULTER.

         14.2 Unless otherwise called for by specific provisions hereunder
reports, notices and other communications from DFCI to COULTER as provided
hereunder shall be sent to:

                  Ms. Bobbie Wallace
                  Director of Immunology
                  Coulter Corporation
                  Coulter Technology Center
                  P.O. Box 169015
                  Miami, Florida 33116-9015

         with a copy to:

--------------------------------------
* Confidential treatment requested

                                      -11-
<PAGE>

                  Wayne A. Barlin
                  Corporate Counsel
                  Coulter Corporation
                  Coulter Technology Center
                  P.O. Box 169015
                  Miami, Florida 33116-9015

         or other individuals or addresses as shall hereafter be furnished by
         written notice to DFCI. For overnight delivery services, the principal
         place of business street address specified at the beginning of this
         AGREEMENT should be used.

                   ARTICLE XV - Indemnification and Insurance

         15.1 COULTER shall indemnify, defend and hold harmless DFCI,
Dana-Farber, Inc., the parent organization of DFCI, and their trustees,
officers, medical and professional staff, employees, and agents and their
respective successors, heirs and assigns (the "Indemnitees") against any
liability, damage, loss or expense (including reasonable attorneys' fees and
expenses of litigation) incurred by or imposed upon the Indemnities, or any one
of them, in connection with any claims, suits, actions, demands or judgments
arising out of any theory of product liability (including but not limited to,
actions in the form of tort or strict liability), concerning any product,
process or service made, used or sold pursuant to any right or license granted
pursuant to this AGREEMENT.

         15.2 Coulter's indemnification under 15.1 shall not apply to any
liability, damage, loss or expense to the extent that it is directly
attributable to the negligent activities, reckless misconduct or intentional
misconduct of the Indemnitees.

         15.3 The party with the obligation to indemnify as hereunder provided
agrees, at its own expense, to provide attorneys reasonably acceptable to the
party(ies) to be indemnified to defend against any actions brought or filed
against any party indemnified hereunder with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought.

         15.4 DFCI shall indemnify, defend and hold harmless COULTER, its
directors, officers, employees and agents and their respective successors, heirs
and assigns (the "COULTER Indemnitees") against any liability, damage, loss or
expense (including reasonable attorneys' fees and expenses of litigation)
incurred by or imposed upon the COULTER Indemnitees, or any one of them, that is
directly attributable to the negligent activities, reckless misconduct or
intentional misconduct of DFCI, Dana-Farber, Inc., and/or their trustees,
officers, employees and agents related to activities to be carried out pursuant
to this AGREEMENT.

         15.5 At such time as any product, process or service relating to, or
developed pursuant to, this AGREEMENT is being commercially distributed or sold
other than for the purpose of obtaining regulatory approvals) by COULTER or by a
Sublicensee, Affiliate or agent of COULTER, COULTER shall, at its sole cost and
expense, procure and maintain policies of comprehensive general liability
insurance in amounts not less than [*] naming the Indemnitees as

--------------------------------------
* Confidential treatment requested

                                      -12-
<PAGE>

additional insureds other than for [*] wherein coverage limits would be [*] and
[*]. Such comprehensive general liability insurance shall provide (a) product
liability coverage and (b) broad form contractual liability coverage for
COULTER's indemnification under Sections 15.1 and 15.3 of this AGREEMENT. If
COULTER elects to self-insure all or part of the limits described above
(including deductibles or retentions which are in excess of [*]), such
self-insurance program must be [*].

         15.6 COULTER shall provide DFCI with written evidence of such insurance
upon request of DFCI. COULTER shall provide DFCI with written notice at least
thirty (30) days prior to the cancellation, non-renewal or material change
involving a substantial reduction or elimination of broad form contractual
liability and/or product liability coverage of such insurance; if COULTER does
not obtain replacement insurance providing comparable coverage within such
thirty (30) day period, DFCI shall have the right to terminate this AGREEMENT as
it relates to a specific Technology(ies) effective at the end of such thirty
(30) day period without any notice or additional waiting periods.

         15.7 COULTER shall maintain such comprehensive general liability
Insurance beyond the expiration or termination of this AGREEMENT during (a) the
period that any product, process, or service, relating to, or developed pursuant
to, this AGREEMENT is being commercially distributed or sold (other than for the
purpose of obtaining regulatory approvals) by COULTER or by a sublicense,
affiliate or agent of COULTER and (b) a reasonable period after the period
referred to in 15.7(a) above which in no event shall be less than [*].

         15.8 In the event any such action is commenced or claim made or
threatened against an Indemnitee(s) or COULTER Indemnitee(s) as to which COULTER
or DFCI, as the case may be, is obligated to indemnify it (them) or hold it
(them) harmless, the party(ies) to be indemnified shall promptly notify the
party with the obligation to indemnify of such event. COULTER or DFCI, as the
case may be shall assume the defense of, and may settle, that part of any such
claim or action commenced or made which relates to the indemnification
obligation. The party obligated to indemnify may take such other steps as may be
necessary to protect itself. The party with the obligation to indemnify shall
not be liable to the party(ies) to be indemnified on account of any settlement
of any such claim of litigation affected without the consent of the party having
the obligation to indemnify. The right of COULTER or DFCI, as the case may be,
to assume the defense of any action shall be limited to that part of the action
commenced against Indemnitees or COULTER Indemnitees which relates to COULTER's
or DFCI's obligation of indemnification and holding harmless.

         15.9 This ARTICLE XV shall survive expiration or termination of this
AGREEMENT.

            ARTICLE XVI - Warranties, Representation and Disclaimers

         16.1 DFCI REPRESENTS AND WARRANTS TO COULTER THAT IT HAS THE FULL
AUTHORITY TO GRANT LICENSES TO COULTER AS HEREIN PROVIDED.

         16.2 DFCI DOES NOT WARRANT THE VALIDITY OF ANY PATENT RIGHTS WHICH MAY
BE LICENSED PURSUANT TO THIS AGREEMENT AND MAKES NO

--------------------------------------
* Confidential treatment requested

                                      -13-
<PAGE>

REPRESENTATION WHATSOEVER WITH REGARD TO THE SCOPE OF ANY PATENT RIGHTS OR THAT
SUCH PATENT RIGHTS MAY BE EXPLOITED BY COULTER OR AN AFFILIATE OR SUBLICENSEE OF
COULTER WITHOUT INFRINGING OTHER PATENTS; PROVIDED HOWEVER, THAT DFCI REPRESENTS
AND WARRANTS THAT IT SHALL TAKE NO ACTION WHICH SHALL JEOPARDIZE ANY SUCH PATENT
RIGHTS AND HAS NO KNOWLEDGE OF ANY THIRD PARTY RIGHTS TO A LICENSED TECHNOLOGY.
IF UNPATENTED BIOLOGICAL MATERIALS ARE LICENSED HEREUNDER, DFCI MAKES NO
REPRESENTATION THAT SUCH MATERIALS OR THE METHODS USED IN MAKING OR USING SUCH
MATERIALS ARE FREE FROM LIABILITY FOR PATENT INFRINGEMENT.

         16.3 DFCI MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, NON-PUBLIC OR OTHER INFORMATION,
OR TANGIBLE RESEARCH PROPERTY, LICENSED OR WHICH OTHERWISE MAY BE PROVIDED TO
COULTER HEREUNDER AND HEREBY DISCLAIMS THE SAME.

                       ARTICLE XVII - Dispute Resolution

         17.1 Any controversy or claim arising out of, or relating to, any
provisions of this AGREEMENT or the breach thereof which cannot otherwise be
resolved by good faith negotiations between the parties or by some form of
alternate dispute resolution other than arbitration shall be resolved by final
and binding arbitration in New York, New York under the rules of the American
Arbitration Association, or the Patent Arbitration Rules if applicable, then
obtaining.

         The arbitration shall be subject to the following terms:

         (a)      The number of arbitrators shall be one (1).

         (b)      The arbitrator shall be an independent, impartial third party
                  having no direct or indirect personal or financial
                  relationship to any of the parties to the dispute, who has
                  agreed to accept the appointment as arbitrator on the terms
                  set out in this Section 17.1.

         (c)      The arbitrator shall be an active or retired attorney, law
                  professor, or judicial officer with at least five (5) years
                  experience in general commercial matters and a familiarity
                  with the laws governing proprietary rights in intellectual
                  property and the Technology in dispute.

         (d)      The arbitrator shall be selected as follows;

                  (i)      Each party shall submit a description of the matter
                           to be arbitrated to the American Arbitration
                           Association at its Regional Office in New York, New
                           York. Said Association shall submit to the parties a
                           list of the arbitrators available to arbitrate any
                           dispute between them. Thereafter, each party shall
                           select, in numerical order, those persons

                                      -14-
<PAGE>

                           on said list acceptable as arbitrators and return the
                           same to the Association. The first arbitrator
                           acceptable to both parties shall be deemed the
                           selected arbitrator with respect to the dispute then
                           at issue under this AGREEMENT. In the event of a
                           failure to select a mutually agreeable arbitrator,
                           the Association shall be requested to submit as many
                           subsequent lists of arbitrators as shall be necessary
                           to effect a mutual selection.

                  (ii)     If the method of selection set out in paragraph d)(i)
                           fails for any reason, then either party may petition
                           any state or federal court in New York having
                           jurisdiction for appointment of the arbitrator in
                           accordance with applicable law, provided that the
                           arbitrator must satisfy the requirements of b) and c)
                           above.

         (e)      The arbitrator shall announce the award in writing accompanied
                  by written findings explaining the facts determined in support
                  of the award, and any relevant conclusions of law.

         (f)      Unless otherwise provided in this Section 17.1 or extended by
                  agreement of the parties, each party shall submit an initial
                  request for designation of an arbitrator within [*] after any
                  request for arbitration, the dispute shall be submitted to the
                  arbitrator within [*] after the arbitrator is selected, and a
                  decision shall be rendered within [*] after the dispute is
                  submitted.

         (g)      The fees of the arbitrator and any other costs and fees
                  associated with the arbitration shall be paid in accordance
                  with the decision of the arbitrator.

         (h)      The arbitrator shall have no power to add to, subtract from,
                  or modify any of the terms or conditions of this AGREEMENT.
                  Any award rendered in such arbitration may be enforced by
                  either party in either the courts of the State of New York or
                  a United States District Court in New York, New York, to whose
                  jurisdiction for such purposes DFCI and Coulter each hereby
                  irrevocably consents and submits.

         17.2 Notwithstanding the forgoing, nothing in this ARTICLE shall be
construed to waive any rights or timely performance of any obligations existing
under this AGREEMENT.

                  ARTICLE XVIII - Restrictions on Use of Names

         18.1 COULTER shall not use the names of DFCI, its related entities, Dr.
Schlossman and other employees within the Division, or any adaptations thereof,
in any advertising, promotional or sales literature, without the prior written
consent of DFCI in each case; provided however, that COULTER (a) may refer to
publications by employees of DFCI in the scientific literature or (b) may state
that a license from DFCI has been granted as herein provided.

--------------------------------------
* Confidential treatment requested

                                      -15-
<PAGE>

         18.2 DFCI, its related entities and Dr. Schlossman and persons under
his supervision shall not use the name of COULTER without the prior written
consent of COULTER; provided however, that they may reference this AGREEMENT or
acknowledge receipt of COULTER reagents or financial support in publications and
presentations.

                      ARTICLE XIX - Independent Contractor

         19.1 For the purpose of this AGREEMENT and all services to be provided
hereunder, both parties shall be, and shall be deemed to be, independent
contractors and not agents or employees of the other. Neither party shall have
authority to make any statements, representations or commitments of any kind, or
to take any action, that will be binding on the other party.

                           ARTICLE XX - Severability

         20.1 If any one or more of the provisions of this AGREEMENT shall be
held to be invalid, illegal or unenforceable, the validity, legality or
enforceability of the remaining provisions of this AGREEMENT shall not in any
way be affected or impaired thereby.

                        ARTICLE XXI - Non-assignability

         21.1 Neither this AGREEMENT nor any part hereof shall be assignable by
either party without the express written consent of the other, which consent
will not be unreasonably withheld. However, either party may assign this
AGREEMENT in connection with the merger, consolidation, transfer or sale of
substantially all of its assets. Any attempted assignment without such consent
shall be void.

                        ARTICLE XXII - Entire AGREEMENT

         22.1 This instrument with its attached, appendices contains the entire
AGREEMENT between the parties hereto. No verbal agreement, conversation, or
representation between any officers, agents, or employees of the parties hereto
either before or after the execution of this AGREEMENT shall affect or modify
any of the terms or obligations herein contained.

                    ARTICLE XXIII - Modifications in Writing

         23.1 No change, modification, extension, termination or waiver of this
AGREEMENT, or any of the provisions herein contained, shall be valid unless made
in writing and signed by a duly authorized representative of each party.

                          ARTICLE XXIV - Governing Law

         24.1 The validity and interpretation of this AGREEMENT and the legal
relations of the parties to it shall be governed by the laws of the Commonwealth
of Massachusetts.

                                      -16-
<PAGE>

                       ARTICLE XXV - Conformity with Law

         25.1 Research funded under this AGREEMENT shall be carried out in
strict compliance with all applicable federal, state and local laws and
regulation, including without limitation, laws and regulations related to equal
opportunity, animal welfare and immigration compliance.

                            ARTICLE XXVI - Captions

         26.1 The captions are provided for convenience and are not to be used
in construing this AGREEMENT.

                          ARTICLE XXVII - Construction

         27.1 The parties agree that they have participated equally in the
formation of this AGREEMENT and that the language herein should not be
presumptively construed against either of them.

                    ARTICLE XXVIII - Priority Of Agreements

         28.1 With respect to a specific licensing transaction where there is a
conflict in terms between this AGREEMENT and the LICENSING AGREEMENT contained
in Appendix A as it may be particularized for that transaction, this AGREEMENT
shall take precedence unless otherwise agreed to by the parties.

                         ARTICLE XXIX - Confidentiality

         29.1 The confidentiality obligations created herein do not extend to
any subject matter which:

         (a)      is in the public domain at the time of the disclosure;

         (b)      becomes known to the public or generally available to the
                  public subsequent to the date it was received hereunder
                  without a breach of this AGREEMENT;

         (c)      was in possession of the party receiving the confidential
                  information at the time of disclosure and was not acquired on
                  a confidential basis from the disclosing party prior to that
                  time, all as can be established by competent proof; and

         (d)      the party receiving the confidential information obtained
                  lawfully from a third party.

                          ARTICLE XXX - Force Majeure

         30.1 If the performance of any part of this AGREEMENT by either party,
or of any obligation under this AGREEMENT is prevented, restricted, interfered
with or delayed by reason

                                      -17-
<PAGE>

of any cause beyond the reasonable control of the party liable to perform,
unless reasonable evidence to the contrary is provided, the party so affected
shall, upon giving written notice to the other party, be excused from such
performance to the extent of such prevention, restriction, interference or
delay, provided that the affected party shall use its reasonable efforts to
avoid or remove such causes for nonperformance and shall continue performance
with the utmost dispatch whenever such causes are removed. When such
circumstance arise, the parties shall discuss what, if any, modification of the
terms of this AGREEMENT may be required in order to arrive at an equitable
solution.

         IN WITNESS WHEREOF, the parties hereto have caused this AGREEMENT to be
executed in quadruplicate by their duly authorized representatives as of the
date first above written.

DANA-FARBER CANCER INSTITUTE (DFCI)COULTER CORPORATION (COULTER

<TABLE>
<CAPTION>
<S>                                                          <C>
By: /s/ BERNARD W. JANICKI                                    By: /s/ WALLACE H. COULTER
    -------------------------------------------------             -------------------------------------------------
    Bernard W. Janicki, Ph.D.                                     Wallace H. Coulter

Title:     Director for Research                              Title:     Chairman of the Board of Directors

WITNESSED BY: /s/ ILLEGIBLE                                   WITNESSED BY: /s/ ILLEGIBLE
              ---------------------------------------                       ---------------------------------------

</TABLE>

Dr. Schlossman acknowledges trading and understanding this AGREEMENT and hereby
agrees to accept responsibility for the research projects funded hereunder and
further agrees to provide any disclosures, submissions or progress reports as
herein required.

/s/ STUART F. SCHLOSSMAN
---------------------------
Stuart F. Schlossman, M.D.

                                      -18-
<PAGE>

                                   APPENDIX A

                               LICENSING AGREEMENT

         Agreement ("AGREEMENT"), effective as of ___________, 19___ ("Effective
Date") by and between the COULTER CORPORATION, a Delaware for-profit,
corporation, with its principal place of business at 11800 South West 147th
Ave., Miami, FL 33196 (hereinafter referred to as "COULTER') and the DANA-FARBER
CANCER INSTITUTE. INC., a Massachusetts non-profit corporation, with its
principal place of business at 44 Binney Street, Boston, Massachusetts, 02115
(hereinafter referred to as "DFCI").

                                   WITNESSETH:

         WHEREAS, DFCI is the owner of certain rights in technology as later
defined herein, subject only, where applicable, to a royalty-free, nonexclusive
license granted to the United States government; and

         WHEREAS, DFCI desires to have such rights utilized to promote the
public interest by granting a license hereunder; and

         WHEREAS, COULTER, utilizes new scientific discoveries from DFCI and
elsewhere to serve humanity by developing commercial products for use by
research scientists and for the diagnosis and treatment of diseases; and

         WHEREAS, COULTER is experienced in research and development of
immunotherapeutic and immunodiagnostic technologies and has demonstrated the
capability of commercializing new scientific discoveries; and

         WHEREAS, COULTER desires to obtain a license to said rights upon the
terms and conditions hereinafter set forth;

         NOW THEREFORE, in consideration of the mutual covenants herein
contained and intending to be legally bound hereby, the parties hereto agree as
follows:

                            ARTICLE I - Definitions

         1.1 "Invention" shall mean _____________together with any Technical
Information as herein defined.

         1.2 "Technical Information" shall mean know-how, non-public
information, tangible research property or anything that provides commercial
advantage which is non-public at the time of this AGREEMENT.

         1.3 "Patent Rights" shall mean any United States or foreign patent
applications or any patents issuing thereon arising from the Invention and owned
by, or assignable to, DFCI as set forth in Appendix A, together with any
division, reissue, continuation, extension, or addition thereof.

<PAGE>

         1.4 "Licensed Products" shall mean any product which is covered in
whole or in part by as issued, unexpired claim or a pending claim in the Patent
Rights and/or which incorporates, is produced by or utilizes the Technical
Information.

         1.5 "Licensed Process" shall mean any process which is covered in whole
or in part by as issued, unexpired claim or a pending claim in the Patent Rights
and/or which incorporates or utilizes the Technical Information.

         1.6 "Field of Use" shall mean ________________________________.

         1.7 "Territory" shall mean the world.

         1.8 "Net Sales" shall mean the revenue derived by COULTER from the
sales of products incorporating Technology developed within the Division to
independent third parties (including Affiliates) less:

         (a)      transportation charges, inclusive of related insurance, or
                  allowances actually paid or granted;

         (b)      trade, quantity, cash or other discounts and brokers' or
                  agents' commissions, if any, allowed and paid by COULTER to
                  independent parties in arms-length transactions;

         (c)      credits or allowances made or given on account of rejects,
                  returns or retroactive price reductions for any amount not
                  collected;

         (d)      any tax or government charge directly on sale or
                  transportation, use or delivery of products paid by COULTER
                  and not recovered from the purchaser.

         Licensed products shall be considered "sold" when invoiced.

         1.9 "Sublicensee" shall mean any corporation, partnership or business
organization which is not an Affiliate of COULTER but to whom COULTER transfers
know-how, rights or products, to enable said party to sell products
incorporating Technology which COULTER has licensed from DFCI.

         1.10 "Affiliate" shall mean any corporation or outer business entity
controlled by, controlling, or under common control with COULTER. For this
purpose "control" means direct or indirect beneficial ownership of greater than
fifty percent (50%) interest in the income or stock of such corporation or other
business.

                               ARTICLE II - Grant

         2.1 DFCI hereby grants to COULTER, subject to all the terms and
conditions of this AGREEMENT including, where applicable, a nonexclusive license
to the United States government the exclusive right and license to make, have
made, use, lease and sell the Licensed

                                      -2-
<PAGE>

Products in the Territory for the Field of Use for the term of this AGREEMENT
unless this grant is sooner terminated according to the terms hereof.

         2.2 DFCI retains the right to [*] the Invention and any Patent Rights
and Technical Information [*] for its own research. DFCI further retains the
right to [*]. DFCI further retains the right to [*] Invention for applications
outside the Field of Use subject to any rights which COULTER may have under its
research support agreement with DFCI effective as of April 1, 1994.

         2.3 COULTER agrees to [*] in assuring that Licensed Products leased or
sold in the United States shall be manufactured substantially in the United
States consistent with federal law and policy.

         2.4  (a) COULTER shall have the right, subject to the terms of this
                  Section, to enter into sublicensing agreements with any other
                  entity other than as Affiliate for the rights, privileges and
                  licenses granted hereunder [*] only during the exclusive
                  period of this AGREEMENT. DFCI shall be informed by written
                  notice of the identity of the Sublicensee.

              (b) COULTER agrees that any sublicenses granted by it shall
                  provide that the obligations to DFCI contained in this
                  AGREEMENT shall be binding upon the Sublicensee.

              (c) COULTER shall pay DFCI an amount [*]. Recording and payment
                  of such royalties shall be made in accordance with the
                  provisions of ARTICLE IV.

              (d) COULTER agrees to forward to DFCI annually a copy of such
                  reports received by COULTER from its Sublicensee during the
                  preceding twelve (12) month period under the sublicenses as
                  shall be pertinent to a royalty accounting under said
                  sublicense agreements.

                          ARTICLE III - Due Diligence

         3.1 COULTER agrees to [*]. [Specific milestones regarding product or
planes development and commercialization may be inserted here.]

         3.2 COULTER's failure to perform in accordance with Section 3.1 shall
be grounds for DFCI to terminate pursuant to Section 7.5 of this AGREEMENT.

         3.3 COULTER shall provide an annual report on its development efforts
to DFCI, which report shall cite specific goals and objectives in
commercializing the licensed technology and progress in meeting these goals and
objectives.

--------------------------------------
* Confidential treatment requested

                                      -3-
<PAGE>

                             ARTICLE IV - Payments

         4.1  (a) COULTER shall pay to DFCI a [*] royalty on Net Sales of a
                  Licensed Product.

              (b) Where such Licensed Product incorporates, a patented
                  technology and the patent has expired, this royalty rate shall
                  be equitably adjusted by the parties to [*].

              (c) Where such Licensed Product does not incorporate patented
                  technology, then this royalty rate shall be equitably adjusted
                  by the parties after [*] from the date of the License to [*].

              (d) Where COULTER must obtain a license from a third party in
                  order to practice the subject Technology developed within the
                  Division, either because [*] or [*] then [*].

         4.2 Upon agreement as to patent strategy between the parties, COULTER
shall [*]. Such expenses shall be [*].

         4.3 Payment of royalties specified in Section 4.1 shall be made by
COULTER to DFCI within [*] after March 31, June 30, September 30 and December 31
each year during the term of this License AGREEMENT covering the quantity of
Licensed Products sold by COULTER during the preceding calendar quarter.

         4.4 All payments to be made under this ARTICLE shall be paid in United
States dollars in Boston, Massachusetts, or at such other place and in such
other way, as DFCI may reasonably designate, without deduction of exchange,
collection or other charges.

         4.5 Only a single royalty shall be paid with respect to any Licensed
Product, irrespective of the number of claims of Patent Rights or Technical
Information utilized.

         4.6 In the event that any payment due hereunder is not made when due,
the payment shall accrue interest beginning on the first day following the due
date as herein specified calculated at the annual rate of the sum of (a) [*]
plus (b), the prime interest rate quoted by the Bank of Boston on the date said
payment is due, the interest being compounded on the last day of each calendar
quarter, provided that in no event shall said annual rate exceed the maximum
legal interest rate in Massachusetts. The payment of such interest shall not
foreclose DFCI from exercising any other rights it may have as a consequence of
the lateness of any payment.

                        ARTICLE V - Reports and Records

         5.1 COULTER shall keep due books of account containing an accurate
record of all data necessary for the determination of the amounts payable under
ARTICLE IV hereof. Said records shall be kept at COULTER's principal place of
business or the principal place of

--------------------------------------
* Confidential treatment requested

                                      -4-
<PAGE>

business of the appropriate division of COULTER to which this AGREEMENT relates.
Said records shall be available for inspection by a certified public accountant
selected by DFCI and reasonably acceptable to COULTER during regular business
hours for three (3) years following the end of the calendar year to which they
pertain in order for DFCI to ascertain the correctness of any report and/or
payment made under this AGREEMENT. The provision of this Section 3.1 shall
survive termination of this AGREEMENT.

         5.2 Within [*] after March 31, June 30, September 30 and December 31,
of each year in which this AGREEMENT is in effect, COULTER shall deliver to DFCI
full, true and accurate reports of its activities and those of its
Sublicensee(s), if any, relating to this AGREEMENT during the preceding three
month period. These reports shall include at least the following:

         (a)      Number of Licensed Products sold;

         (b)      Total billings for Licensed Products sold; where applicable,

         (c)      An accounting of all Licensed Processes used or sold;

         (d)      Deductions applicable to a determination of Net Sales;

         (e)      Total royalties due.

         5.3 With each such report, COULTER shall pay to DFCI the royalties due
and payable as Provided for in Section 4.1. If no royalties are due, COULTER
shall so report.

                ARTICLE VI - Patent Prosecution and Infringement

         6.1 DFCI shall apply for, seek prompt issuance of, and maintain during
the term of this AGREEMENT any Patent Rights in the United States and in foreign
countries. [*].

         6.2 Upon agreement between the parties, [*], whether such fees and
costs were incurred before or after the date of this AGREEMENT.

         6.3 If at any time during the term of this AGREEMENT, COULTER furnishes
to DFCI reasonably convincing written evidence of an infringement of a patent
included in the Patent Rights covering the Invention, and DFCI shall within [*]
after receipt of such evidence fail to cause such infringement to terminate or
to bring a suit or action to compel termination, then COULTER shall have the
right, but not the obligation, to bring such suit or action to compel
termination and shall have the right for such purpose to join DFCI as a party
plaintiff at COULTER's expense. DFCI independently shall have the right to join
any such suit or action brought by COULTER and, in such event, shall pay
one-half of the cost of such suit or action from the date of joining. If COULTER
brings such suit or action, then [*]. No settlement, consent judgment or other
voluntary final disposition of the suit may be entered into without the consent
of DFCI, which consent shall, not be unreasonably withheld. Any damages
recovered by such suit or action shall be first used to reimburse each party
hereto for the cost of such suit or action (including attorneys' fees) actually
paid by each party hereto as the case may be, then to

--------------------------------------
* Confidential treatment requested

                                      -5-
<PAGE>

reimburse DFCI for any reduction of royalties, and the residue, if any, shall
belong to COULTER.

         6.4 In the event that a judicial process is initiated against COULTER
alleging invalidity or noninfringement of any of the Patent Rights, DFCI, at its
sole option, shall have the right, within thirty (30) days after commencement of
such action, to intervene and take over the sole defense of the action at its
own expense. During pendency of such action, [*].

         6.5 In any infringement suit as either party may institute to enforce
the Patent Rights pursuant to this AGREEMENT, the other party hereto shall, at
the request and expense of the party initiating such suit, cooperate in all
respects and, to the extent possible, have its employees testify when requested
and make available relevant records, papers, information, samples and the like.

                       ARTICLE VII - Term and Termination

         7.1 Unless earlier terminated as hereinafter provided, this AGREEMENT
shall remain an exclusive AGREEMENT and in full force and effect as long as
Licensed Products are being developed or sold.

         7.2 If COULTER, its Affiliates, Sublicensees or assignees shall cease
to carry on its (their) business with respect to the Invention, this AGREEMENT
shall terminate upon notice by DFCI.

         7.3 Should COULTER fail to pay DFCI such royalties as are due and
payable hereunder, DFCI shall have the right to terminate this AGREEMENT on [*]
written notice, unless COULTER shall pay DFCI within the [*] notice period, all
such royalties and interest that are due and payable. Upon the expiration of the
[*] period, if COULTER shall not have paid all such royalties and interest due
and payable, DFCI, at its sole option, may immediately terminate this AGREEMENT
and all rights, privileges and license hereunder granted.

         7.4 COULTER shall have the right to terminate this AGREEMENT at any
time upon [*] written notice to DFCI, and upon payment of all amounts due DFCI
through the effective date of termination.

         7.5 In the event that either party shall default in the performance of
its obligations under this AGREEMENT and shall fail to remedy such default
within [*] for breaches of financial obligations and [*] for breaches of
non-financial obligations after written notice from the other party, the
nondefaulting party shall be entitled upon giving written notice to immediately
terminate this AGREEMENT; provided however, that if the defaulting party has
undertaken and continues to undertake, good faith efforts to cure, the
defaulting party shall be granted another [*] to cure.

         7.6 Upon termination of this AGREEMENT for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination. COULTER and say Sublicensee
thereof may, after the effective date of such

--------------------------------------
* Confidential treatment requested

                                      -6-
<PAGE>
termination, sell all Licensed Products which are in inventory at the time of
termination, and complete and sell Licensed Products which COULTER can clearly
demonstrate were in the process of manufacture at the time of such termination,
provided that COULTER shall pay to DFCI the royalties thereon as required by
ARTICLE IV of this AGREEMENT and shall submit the reports required by ARTICLE V
hereof on the sales of Licensed Products.

         7.7 Upon termination of this AGREEMENT for any reason, any sublicense
not then in default shall continue in full force and effect except that DFCI,
shall be substituted in place of the sublicensor.

  ARTICLE VIII - Indemnification and Insurance - Indemnification and Insurance

         8.1 COULTER shall indemnify, defend and hold harmless DFCI,
Dana-Farber, Inc., the parent organization of DFCI, and their trustees,
officers, medical and professional staff, employers, and agents and their
respective successors, heirs and assigns (the "Indemnitees"), against any
liability, damage, loss or expense (including reasonable attorneys' fees and
expenses of litigation) incurred by or imposed upon the Indemnitees, or any one
of them, in connection with any claims, suits; actions, demands or judgments
arising out of any theory of product liability (including, but not limited to,
actions in the form of tort or strict liability), concerning any product,
process or service made, used or sold pursuant to any right or license granted
pursuant to this AGREEMENT.

         8.2 COULTER's indemnification under 8.1 shall not apply to any
liability, damage, loss or expense to the extent that it is directly
attributable to the negligent activities, reckless misconduct or intentional
misconduct of the Indemnitees.

         8.3 The party with the obligation to indemnify as hereunder provided
agrees, at its own expense, to provide attorneys reasonably acceptable to the
party(ies) to be indemnified to defend against any actions brought or filed
against any party indemnified hereunder with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought.

         8.4 DFCI shall indemnify, defend and hold harmless COULTER, its
directors, officers, employees and agents and their respective successors, heirs
and assigns (the "COULTER Indemnitees") against any liability, damage, loss or
expense (including reasonable attorneys' fees and expenses of litigation)
incurred by or imposed upon the COULTER Indemnitees, or any one of them, that is
directly attributable to the negligent activities, reckless misconduct or
intentional misconduct of DFCI, Dana-Farber Inc., and/or their trustees,
officer, employees and agents related to activities to be carried out pursuant
to this AGREEMENT.

         8.5 At such time as any product, process or service relating to, or
developed pursuant to, this AGREEMENT is being commercially distributed or sold
(other than for the purpose of obtaining regulatory approvals) by COULTER or by
a Sublicensee, Affiliate or agent of COULTER, COULTER shall, at its sole cost
and expense, procure and maintain policies of comprehensive general liability
insurance in amounts not less than [*] naming the Indemnitees as additional
insureds other than for [*] wherein coverage limits would be [*]. Such
comprehensive general liability insurance shall provide (a) product liability
coverage and (b) broad form contractual liability coverage for COULTER's
Indemnification under Sections

--------------------------------------
* Confidential treatment requested

                                      -7-
<PAGE>

8.1 and 8.3 of this AGREEMENT. If COULTER elects to self-insure all or part of
the limits described above (including deductibles or retentions which are in
excess of [*].

         8.6 COULTER shall provide DFCI with written evidence of such insurance
upon request of DFCI. COULTER shall provide DFCI with written notice at least
thirty (30) days prior to the cancellation, non-renewal or material change
involving a substantial reduction or elimination of broad form contractual
liability and/or product liability coverage of such insurance; if COULTER does
not obtain replacement insurance providing comparable coverage within such
thirty (30) day period, DFCI shall have the right to terminate this AGREEMENT as
it relates to a specific Technology(ies) effective at the end of such thirty
(30) day period without any notice or additional waiting periods.

         8.7 COULTER shall maintain such comprehensive general liability
insurance beyond the expiration or termination of this AGREEMENT during (a) the
period that my product, process, or service, relating to, or developed pursuant
to, this AGREEMENT is being commercially distributed or sold (other than for the
purpose of obtaining regulatory approvals) by COULTER or by a Sublicensee,
affiliate or agent of COULTER and (b) a reasonable period after the period
referred to in 8.7(a) above which in no event shall be less than [*].

         8.8 In the event any action is commenced or claim made or threatened
against an Indemnitee(s) or COULTER Indemnitee(s) as to which COULTER or DFCI,
as the case may be, is obligated to indemnify it (them) or hold it (them)
harmless, the party(ies) to be indemnified shall promptly notify the party with
the obligation to indemnify of such event. COULTER or DFCI, as the case may be,
shall assume the defense of, and may settle, that part of such claim or action
commenced or made which relates to the indemnification obligation. The party
obligated to indemnify may take such other steps as may be necessary to protect
itself. The party with the obligation to indemnify shall not be liable to the
party(ies) to be indemnified on account of any settlement of any such claim or
litigation affected without the consent of the party having the obligation to
indemnify. The right of COULTER or DFCI, as the case may be, to assume the
defense of any action shall be limited to that part of the action commenced
against Indemnitees or COULTER Indemnitees which relates to COULTER's or DFCI's
obligation of indemnification and holding harmless.

         8.9 This ARTICLE VIII shall survive expiration or termination of this
AGREEMENT.

            ARTICLE IX - Warranties, Representation and Disclaimers

         9.1 DFCI REPRESENTS AND WARRANTS TO COULTER THAT HAS THE FULL AUTHORITY
TO GRANT LICENSES TO COULTER AS HEREIN PROVIDED.

         9.2 DFCI DOES NOT WARRANT THE VALIDITY OF ANY PATENT RIGHTS WHICH MAY
BE LICENSED PURSUANT TO THIS AGREEMENT AND MAKES NO REPRESENTATION WHATSOEVER
WITH REGARD TO THE SCOPE OF ANY PATENT RIGHTS OR THAT SUCH PATENT RIGHTS MAY BE
EXPLOITED BY COULTER OR AN

--------------------------------------
* Confidential treatment requested

                                      -8-
<PAGE>

AFFILIATE OR SUBLICENSEE OF COULTER WITHOUT INFRINGING OTHER PATENTS; PROVIDED
HOWEVER, THAT DFCI REPRESENTS AND WARRANTS THAT IT SHALL TAKE NO ACTION WHICH
SHALL JEOPARDIZE ANY SUCH PATENT RIGHTS AND HAS NO KNOWLEDGE OF ANY THIRD PARTY
RIGHTS TO A LICENSED TECHNOLOGY. IF UNPATENTED BIOLOGICAL MATERIALS ARE LICENSED
HEREUNDER, DFCI MAKES NO REPRESENTATION THAT SUCH MATERIALS OR THE METHODS USED
IN MAKING OR USING SUCH MATERIALS ARE FREE FROM LIABILITY FOR PATENT
INFRINGEMENT.

         9.3 DFCI MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, NON-PUBLIC OR OTHER INFORMATION
OR TANGIBLE RESEARCH PROPERTY, LICENSED OR WHICH OTHERWISE MAY BE PROVIDED TO
COULTER HEREUNDER AND HEREBY DISCLAIMS THE SAME.

                              ARTICLE X - Notices

         10.1 Unless otherwise called for by specific provisions hereunder
report, notices and other communications from COULTER to DFCI as provided
hereunder shall be sent to:

                  Dr. Bernard W. Janicki
                  Director for Research
                  Dana-Farber Cancer Institute
                  44 Binney Street
                  Boston, MA 02115

         with a copy to:

                  Kenneth P. Trevett, Esq.
                  General Counsel
                  Dana-Farber Cancer Institute
                  44 Binney Street
                  Boston, MA 02115

         or other individuals or addresses as shall hereafter be furnished by
         written notice to COULTER.

         10.2 Unless otherwise called for by specific provisions hereunder,
reports, notices and other communications from DFCI to COULTER as provided
hereunder shall be sent to:

                  Ms. Bobbie Wallace
                  Director of Immunology
                  Coulter Corporation
                  Coulter Technology Center
                  P.O. Box 169015
                  Miami, Florida 33116-9015

                                      -9-
<PAGE>

         with a copy to:

                  Corporate Counsel
                  Coulter Corporation
                  Coulter Technology Center
                  P.O. Box 169015
                  Miami, Florida 33116-90l5

         or other individuals or addresses as shall hereafter be furnished by
         written notice to DFCI.

                            ARTICLE XI - Arbitration

         11.1 Any controversy or claim arising out of, or relating to, any
provisions of this AGREEMENT or the breach thereof which cannot otherwise be
resolved by good faith negotiations between the parties or by some form of
alternate dispute resolution other than arbitration shall be resolved by final
and binding arbitration in New York, New York under the rules of the American
Arbitration Association, or the Patent Arbitration Rules if applicable, then
obtaining.

         The arbitration shall be subject to the following terms:

         (a)      The number of arbitrators shall be one (1).

         (b)      The arbitrator shall be an independent, impartial third party
                  having no direct or indirect personal or financial,
                  relationship to any of the parties to the dispute, who has
                  agreed to accept the appointment as arbitrator; on the terms
                  set out in this Section 11.1.

         (c)      The arbitrator shall be an active or retired attorney, law
                  professor, or judicial officer with at least five (5) years
                  experience in general commercial matters and a familiarity
                  with the laws governing proprietary rights in intellectual
                  property and the Technology in dispute.

         (d)      The arbitrator shall be selected as follows:

                  (1)      Each party shall submit a description of the matter
                           to be arbitrated to the American Arbitration
                           Association at its Regional Offices in New York, New
                           York. Said Association shall submit to the parties a
                           list of the arbitrators available to arbitrate any
                           dispute between them. Thereafter, each party shall
                           select, in numerical order, those persons on said
                           list acceptable as arbitrators and return the same to
                           the Association. The first arbitrator acceptable to
                           both parties shall be deemed the selected arbitrator
                           with respect to the dispute then at issue under this
                           AGREEMENT. In the event of a failure to select a
                           mutually agreeable arbitrator, the Association shall
                           be requested to submit as many subsequent lists of
                           arbitrators as shall be necessary to effect a mutual
                           selection.

                                      -10-
<PAGE>

                  (2)      If the method of selection set out in paragraph d)(i)
                           fails for any reason, then either party may petition
                           any state or federal court in New York having
                           jurisdiction for appointment of the arbitrator in
                           accordance with applicable law, provided that the
                           arbitrator must satisfy the requirements of b) and c)
                           above.

         (e)      The arbitrator shall announce the award in writing accompanied
                  by written findings explaining the facts determined in support
                  of the award, and any relevant conclusions of law.

         (f)      Unless otherwise provided in this Section 11.1 as extended by
                  agreement of the parties, each party shall submit an initial
                  request for designation of an arbitrator within [*] after any
                  request for arbitration, the dispute shall be submitted to the
                  arbitrator within [*] after the arbitrator is selected, and a
                  decision shall be rendered within [*] after the dispute is
                  submitted.

         (g)      The fees of the arbitrator and any other costs and fees
                  associated with the arbitration shall be paid in accordance
                  with the decision of the arbitrator.

         (h)      The arbitrator shall have no power to add to, subtract from,
                  or modify any of the terms or conditions of this AGREEMENT.
                  Any award rendered in such arbitration may be enforced by
                  either party in either the courts of the State of New York or
                  a United States District Court in New York, New York, to whose
                  jurisdiction for such purposes DFCI and COULTER each hereby
                  irrevocably consents and submits.

         11.2 Notwithstanding the foregoing, nothing in this ARTICLE shall be
construed to waive any rights or timely performance of any obligations existing
under this AGREEMENT.

                   ARTICLE XII - Restrictions on Use of Names

         12.1 COULTER shall not use the names of DFCI, its related entities, Dr.
Schlossman and other employees within the Division, or any adaptations thereof,
in any advertising, promotional or sales literature, without the prior written
consent of DFCI in each case; provided however, that COULTER (a) may refer to
publications by employees of DFCI in the scientific literature or (b) may state
that a license from DFCI has been granted as herein provided.

         12.2 DFCI, its dated entities and Dr. Schlossman and persons under his
supervision shall not use the name of COULTER without the prior written consent
of COULTER; provided however, that they may reference this AGREEMENT or
acknowledge receipt of COULTER reagents or financial support in publications and
presentations.

                     ARTICLE XIII - Independent Contractor

         13.1 For the purpose of this AGREEMENT and all services to be provided
hereunder, both parties shall be, and shall be deemed to be, independent
contractors and not agents or

--------------------------------------
* Confidential treatment requested

                                      -11-
<PAGE>

employees of the other. Neither party shall have authority to make any
statements, representation or commitments of any kind, or to take any action,
that will be binding on the other party.

                           ARTICLE XIV - Severability

         14.1 If any one or more of the provisions of this AGREEMENT shall be
held to be invalid, illegal or unenforceable, the validity, legality or
enforceability of the remaining provisions of this AGREEMENT shall not in any
way be affected or impaired thereby.

                         ARTICLE XV - Non-assignability

         15.1 Neither this AGREEMENT nor any part hereof shall be assignable by
either party without the express written consent of the other, which consent
will not be unreasonably withheld. However, either party may assign this
AGREEMENT in connection with the merger, consolidation, transfer or sale of
substantially all of its assets. Any attempted assignment without such consent
shall be void.

                         ARTICLE XVI - Entire AGREEMENT

         16.1 This instrument contains the entire AGREEMENT between the parties
hereto. No verbal agreement, conversation or representation between any
officers, agents, or employees of the parties hereto either before or after the
execution of this AGREEMENT shall affect or modify any of the terms or
obligations herein contained.

                     ARTICLE XVII - Modification in Writing

         17.1 No change, modification, extension, termination or waiver of this
AGREEMENT, or any of the provisions herein contained, shall be valid unless made
in writing and signed by a duly authorized representative of each party.

                         ARTICLE XVIII - Governing Law

         18.1 The validity and interpretation of this AGREEMENT and the legal
relations of the parties to it shall be governed by the laws of the Commonwealth
of Massachusetts .

                             ARTICLE XIX - Captions

         19.1 The captions are provided for convenience and are not to be used
in construing this AGREEMENT.

                           ARTICLE XX - Construction

         20.1 The parties agree that they have participated equally in the
formation of this AGREEMENT and that the language herein should not be
presumptively construed against either of them.

                                      -12-
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this AGREEMENT to be
executed in quadruplicate by their duly authorized representatives as of the
date first above written.

<TABLE>
<CAPTION>
<S>                                           <C>
DANA-FARBER CANCER INSTITUTE (DFCI)           COULTER CORPORATION (COULTER)

BY:                                            By:
    --------------------------------------         ------------------------------------
           Bernard W. Janicki. Ph. D.
Title: Director for Research                   Title:

WITNESSED BY:                                  WITNESSED BY:

------------------------------------------     ----------------------------------------
</TABLE>

                                      -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]